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In recent years, the epithelial-mesenchymal transition (EMT), in which epithelial cells 
lose their epithelial characteristics and gain mesenchymal features, has emerged as a 
process crucial in cancer progression. Specifically, EMT induces a phenotypic, molecular 
and behavioural change in carcinoma cells, permitting them to invade and metastasise. In 
our study on breast cancer tissue using microarray analysis validated by quantitative real-
time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC), we 
attempted to investigate genes that are differentially expressed in breast cancer 
progression, and determine at which point EMT-related genes become up- or down-
regulated. Overall, 65 EMT-related genes were identified; 36 at the normal to ductal 
carcinoma in situ (DCIS) transition and 29 at the DCIS to invasive ductal carcinoma 
(IDC) transition. The results of our study lead us to propose that EMT is a multi-step 
process, as opposed to an all-or-nothing event. Instead, changes in gene and protein 
expression related to EMT can and do occur as early as the normal to DCIS transition, 
but further accumulate as the cancer progresses from DCIS to IDC, eventually 
culminating in phenotypic changes sufficient for cellular invasion and metastasis.  
 
Beginning with subtle losses of epithelial markers such as claudins and cytokeratins in 
DCIS, followed by gain of mesenchymal markers such as N-cadherin, cadherin-11 and 
SPARC in IDC, tumour cells continually undergo EMT. Other noteworthy EMT-related 
genes that were identified to be upregulated included genes involved in cell adhesion 
(lumican, decorin, versican), proteolysis (matrix metalloproteases, cathepsins), regulation 
  vii 
 of transcription (twist, HOXB7, TCF4) and in signal transduction (PDGF receptor-β, 
cycloxygenase-1, S100A4 and BMP4). EMT-related genes that were downregulated 
included genes also involving cell adhesion (p120ctn, laminin-β-3, plakophilin 1), 
proteolysis (maspin), regulation of transcription (EGR1, EGR2) and in signal 
transduction (frizzled-related protein, PI3-kinase regulatory subunit 1 and TGF-β receptor 
II). Following up our findings, we performed IHC on four candidate proteins and found 
that keratin 14 and maspin were significantly downregulated at the normal to DCIS 
transition (53% and 33% of cases, respectively), while N-cadherin and SPARC were 
significantly upregulated at the DCIS to IDC transition (27% and 73% of cases, 
respectively).  
 
Additionally, in terms of technique and approach, we were able to successfully combine 
laser capture microdissection, RNA amplification and microarray technologies to 
generate epithelial specific gene expression profiles of premalignant (normal mammary 
epithelia), pre-invasive (DCIS) and invasive (IDC) stages of breast cancer from discrete 
subpopulations of cells within histologically complex tumour specimens. This approach 
is useful because it eliminates confounding factors such as tumour stroma and interpatient 
variability, making the results from the expression profiling more meaningful. Already, 
much work has been done to show that EMT is associated with poorer prognosis and 
decreased survival. Therefore, it is imperative that the chronology of EMT events and 
their trigger mechanism are elucidated because identification of new EMT inhibitors 
could hold the promise of novel cancer treatment options. 
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1.1 Breast Cancer 
1.1.1 Incidence of Breast Cancer  
Cancer of the breast in women is a major health burden worldwide. It is the most 
common cause of cancer among women both in developed and developing countries and 
is the leading cause of cancer-associated deaths in women. In 2007, the global incidence 
of breast cancer in women was 1,301,867 of which 464,854 deaths was estimated1. 
According to the Singapore Cancer Registry, breast cancer has remained the most 
frequent cancer among women over the last thirty-five years with a continuing upward 
trend in incidence (Figure 1).  Of the 5500 cases reported in 1998 to 2002, the mortality 








Figure 1. Data extracted from the Singapore Cancer Registry Report No. 6: 
Trends in Cancer Incidence in Singapore 1968-2002. The incidence of breast 















Breast Cancer Incidence 672 859 1235 1727 2621 3570 5500
Percentage of Breast Cancer Cases 






























In terms of histopathology, the most common diagnosis was invasive ductal carcinoma 
(IDC), accounting for 79.2% or 4317 cases of a total of 5500 cases in 1998 to 2002. 
Other frequent  histological types include lobular carcinoma (4.5%), mucinous 
adenocarcinoma (2.9%), carcinoma NOS (2.6%), phyllodes tumour NOS (1.7%), 
infiltrating duct and lobular carcinoma (1.6%), papillary carcinoma (1.0%) and medullary 
carcinoma (1.0%)2.  
 
1.1.2 Etiology of Breast Cancer 
As with many types of cancers, the etiology of breast cancer is difficult to pin-point. The 
two most prominent risk factors are gender and age. Recent data from the Singapore 
Cancer Registry revealed that women in the age group of 55 to 59 years experience the 
highest risk and that 54% of all cases occurred in women 50 years of age and older2. 
Among ethnic groups, Malay and Indian women have approximately 20% lower risk than 
that of Chinese women2.  Reproductive hormones are thought to influence cancer risk 
through effects on cell proliferation, growth and DNA damage. Early menarche (<12 
years), older age at menopause (>55 years), older age at first pregnancy (>30 years) and 
fewer number of pregnancies may increase risk of breast cancer3,4. The lower parity and 
later age at first pregnancy of women in developed countries might account for the higher 
incidence of breast cancer in these regions, relative to developing countries5. Recent use 
of oral contraceptives (OC)6 and combination hormone replacement therapy (HRT)7 may 




Some modifiable susceptible factors include postmenopausal obesity, physical inactivity, 
alcohol consumption, nutrition, environment and stress.  
 
Given the myriad of risk factors that will likely exist in a women’s lifetime, perhaps the 
single most important and impactful risk factor would be a familial history of breast 
cancer, emphasising the role of genetics in the pathology of breast cancer. About 20 to 
30% of women diagnosed with breast cancer have a family history of breast cancer. It is 
estimated that 5 to 10% of breast cancer cases result from inherited mutations or 
alterations in the Breast Cancer Associated Gene 1 and 2 (BRCA1 and BRCA2)4. These 
mutations are present in far less than 1% of the general population8.  From population-
based studies, women with BRCA1 mutations are estimated to have a 65% risk for 
developing breast cancer by age 70; 45% if they inherited BRCA2 mutations9. Other 
genes that strongly influence breast cancer include estrogen receptor (ER) and the Human 










1.1.3 Progression of Breast Cancer 
Breast cancer begins in breast tissue, which is made up of glands for milk production, 
called lobules and the ducts that connect lobules to the nipple. The remainder of the 
breast is made up of fatty, connective and lymphatic tissue. In general, although not 
always, breast cancer progression occurs in a sequence of pathologically defined stages.  
 
The precursor for the most common histological type of breast cancer, invasive ductal 
carcinoma (IDC), is termed “hyperplasia of usual type” (HUT) which can develop into 
non-invasive atypical ductal hyperplasia (ADH) and further progress into pre-invasive 
ductal carcinoma in-situ (DCIS). DCIS is characterised by limited proliferation of 
malignant epithelial cells within the duct, with no evidence of invasion across the 
basement membrane. Untreated, DCIS may progress to invasive ductal carcinoma (IDC) 
following infiltration of malignant epithelial cells across the basement membrane and 
into the stroma10,11 (Figure 2). Beyond this point, the patient is at high risk of metastatic 
cancer and prognosis becomes significantly poorer. Metastasis is responsible for more 
























Figure 2. Anatomy of the breast and 
ductal carcinoma. (I) Range of ductal 
carcinoma (II) Normal breast anatomy 
(III) Ductal carcinoma in situ (IV) 
Invasive ductal carcinoma. 
Key for Figure: A: ducts, B: lobules, C: 
dilated section of duct to hold milk, D: 
nipple, E: fat, F: pectoralis major muscle, 
G: chest wall/rib cage 
Key for Enlargement: (II) A: normal duct 
cells, B: basement membrane, C: lumen 
(III) A: normal duct cells, B: ductal cancer 
cells, C: basement membrane, D: lumen 
(IV) A: normal duct cells, B: ductal cancer 
cells breaking through the basement 
membrane, C: basement membrane 










The metastatic cascade comprises numerous steps, including acquisition of invasiveness, 
escape from the primary tumour site, penetration of local stroma and intravasation into 
local vascular or lymphatic vessels. At secondary sites, the cells can extravasate and 
either remain solitary (micrometastasis) or undergo expansion to form a metastatic 
carcinoma. It is thought that a process known as epithelial-mesenchymal transition 
(EMT) can occur during any of these events, but especially during the acquisition of 
invasiveness, while mesenchymal-epithelial transition (MET) can occur in secondary 









Figure 3. EMT and MET in carcinoma progression. Epithelial carcinoma cells 
undergo EMT to escape the mass (1, 2), seeding minimal residual disease (3) or 
establish a new malignancy (4). Cells that have undergone EMT to exhibit 
mesenchymal phenotype are well-equipped to intravasate into local lymphovascular 
systems (5) and may remain mesenchymal in the circulation (6). This will aid their 
extravasation (7) where they may persist as micrometastasis in bone marrow (8) or 
revert to epithelial via MET to establish a macrometastases capable of bone 








1.2 Epithelial-Mesenchymal Transition (EMT) 
EMT describes the process in which epithelial cells lose their epithelial characteristics 
and gain mesenchymal features, resulting in the acquisition of cellular motility, 
invasiveness, scattering and resistance to anoikis13. The defining phenotypic hallmarks of 
EMT in a cell include the derangement of apico-basal polarity and cell-to-cell adhesion 
while increasing in cell shape plasticity. Often, but not always, the cell gains a spindle-
shaped, fibroblastoid phenotype that is more flexible, individualistic and motile14 (Figure 
4). It is important to note that while the term EMT encompasses a spectrum of molecular, 
phenotypic and behavioral changes, it does not necessarily refer to a complete lineage 






























Figure 4. Morphologic and phenotypic differences between well-differentiated 
epithelial cells and highly invasive carcinoma cells.  Figure and description were 




Core molecular elements of EMT include the downregulation of E-cadherin (adherens 
junction protein), claudins and occludins (tight junction proteins) and desmoplakins 
(desmosome proteins). Expression of epithelial intermediate filaments, cytokeratins, is 
also typically reduced. On the other hand, mesenchymal intermediate filaments, such as 
vimentin, and specific cadherins that promote motility such as N-cadherin and OB-
cadherin increase in expression. Extracellular matrix components such as fibronectin, 
osteonectin (SPARC) and collagen precursors, as well as specific integrins and matrix 
metalloproteases (MMP) are also upregulated. In addition, certain proteins and 
transcription factors that are thought to be involved in EMT accumulate in the nucleus, 
for example, β-catenin, Smad-2/3, Snail and Twist. A summary of common EMT 
markers is listed is Table 1.  
  
 Table 1. EMT Markers. Epithelial markers are commonly downregulated while 






















EMT is controlled by at least six major signaling pathways that are also involved in early 
embryonic development, that is, the Wnt, Hedgehog, Notch, NF-κB, TGF-β, and receptor 
tyrosine kinase (RTK) pathways. These pathways are often dysregulated in cancer and 
often cooperate to drive EMT15-18. It is believed that EMT is induced by signals from the 
tumour microenvironment such as those given out by endothelial cells, lymphocytes, 
macrophages and fibroblasts. Growth factors such as transforming growth factor (TGF)-
β, hepatocyte growth factor (HGF), epidermal growth factor (EGF), platelet derived 
growth factor (PDGF), insulin-like growth factors (IGFs), fibroblast growth factors 
(FGFs) and tumour necrosis factor (TNF)-α activate signal transduction pathways that 
promote EMT in cancer15,19-22. Summary of the diverse signal transduction pathways 














Figure 5. Various signaling cascades involved in EMT. The transition from a well-
differentiated epithelial cell to a highly invasive carcinoma cell involves diverse 
signal transduction cascades. These signaling pathways are activated in response to 
various cytokines and involve a number of downstream effector molecules. These 
pathways converge to initiate expression changes that promote cell motility, 
invasiveness and metastasis. The Wnt, Notch and Hedgehog signaling pathways are 
not represented here but nevertheless have a major role in EMT. Figure and 




















1.2.1 EMT in Normal Development 
Elizabeth D. Hay who was first to coin the term epithelial-to-mesenchymal 
transformation some 40 years ago initially discovered the crucial importance of EMT in 
gastrulation during embryogenesis23 and made beautiful drawings then, illustrating not 
only the transformation to mesenchymal phenotype but also the reversion to epithelial 
character23,24 (Figure 6). EMT is a highly conserved, fundamental process that governs 
morphogenesis in multicellular organisms. In humans, EMT plays a role in gastrulation 
during embryogenesis. In the absence of EMT, development cannot proceed past the 
blastocyst stage25. Later in development, EMT participates in the formation of numerous 
organs and tissues, such as the heart, the musculoskeletal system, craniofacial structures 
and the peripheral nervous system, while in the adult, EMT-like processes occur during 
wound healing. The reverse of EMT, known as mesenchymal-epithelial transition (MET) 
also occurs in normal development, for example, during somitogenesis and kidney 
morphogenesis17.  
  
Figure 6. First EMT and MET drawings made by Hay, in 1967, from 
observations of the developing chick embryo. The process is transient and 
reversible, which is why the preferred term is now transition, as opposed to 
transformation. (EMT denotes epithelial-mesenchymal transition; MET denotes 











1.2.2 EMT in Breast Cancer  
Recognition of epithelial-to-mesenchymal transition (EMT) is relatively new in 
oncology. The number of publications in which this phrase has been used has risen 15-
fold since 2001, making EMT currently one of the hottest topics in medical science20. A 
landmark review written by Jean Paul Thiery in 200225 gave a very compelling argument 
and comprehensive introduction to the occurrence of EMT in cancer progression. Indeed, 
many epithelial tumours hijack the EMT mechanism to gain metastatic capacity. 
 
One of the earliest evidence for EMT in breast cancer was shown in breast cancer cell 
lines by Thomson et al. in 1992.  They showed that MCF-7 cells, which exhibit 
cobblestone morphology in culture, express abundant cytokeratin and negligible 
vimentin. In contrast, MDA-MB-231 and MDA-MB-435, which are highly 
individualistic in culture and show higher invasiveness in vitro, completely lack 
cytokeratin staining but abundantly express vimentin26. In addition, the PMC42-LA 
human breast cell line which initially express cytokeratin strongly and vimentin weakly, 
adopted a strong vimentin expression and reduced cytokeratin expression upon treatment 
with EGF for 3 days27. Sommers et al. hypothesised that a breast cancer cell line with an 
epithelial phenotype could undergo transition into a fibroblastic phenotype and showed 
that adriamycin (doxorubicin)-resistant MCF-7 cell lines underwent this transition. These 
cells express vimentin and have diminished cell adhesion molecules such as keratin 19, 
ovomorulin, desmoplakins and zonula occludens (ZO)-1. Curiously, it appears that 




uvomorulin, desmoplakins and ZO-1 or increase in vitro invasiveness, leading them to 
conclude that while vimentin is a marker for a fibroblastic and invasive phenotype in 
breast cancer cells, vimentin does not by itself give rise to this phenotype28. The 
relevance of the mesenchymal state was reinforced by the study of Zjachowski et al. who 
found that expression of keratin 19 was consistently elevated in less aggressive breast 
cancer cell lines while vimentin was consistently overexpressed in the more highly 
aggressive cell lines29.  
 
Downregulation of E-cadherin has been shown in breast cancer cell lines that are invasive 
in vitro30,31. This downregulation is thought be to the result of promoter hypermethylation 
of the CDH1 gene and less frequently, mutational inactivation or loss of heterozygosity31. 
In addition, a number of transcriptional repressors of E-cadherin have been identified in 
recent years, such as Snail32, Slug33, SIP-1/ZEB-234, δEF1/ZEB-135, E12/E4736, Twist37, 
CBF-A/HNRPAB38, HOXB739 and Goosecoid40. When expressed in a variety of cell 
types, these factors act to repress E-cadherin expression to consequently promote EMT in 
vitro. For this reason, these transcription factors are often dubbed “EMT inducers”. In 
terms of breast cancer tissue, consistent downregulation of E-cadherin, coupled with 
association with poor prognosis and increased metastasis, have been strongly 
demonstrated in invasive lobular carcinomas, but not so in invasive ductal carcinomas41-
43. The expression of EMT inducers in breast carcinomas have also been reported and 
their overexpression is usually related to increased tumour aggressiveness or recurrence, 




While E-cadherin is usually noted to be downregulated in invasive cell lines, Nieman et 
al. showed that it is the expression of N-cadherin that is responsible for cellular motility 
and the resulting increase of invasiveness. Increased expression of N-cadherin has been 
detected in breast carcinomas, particularly more so in an aggressive subtype known as 
invasive micropapillary carcinoma45.  
 
In recent years, a number of studies involving gene expression profiling of breast cancer 
have been conducted in an attempt to identify more EMT-related genes or discover an 
EMT-transcriptomic signature. Indeed, many EMT-related genes have been identified by 
this method. In 2001, Zjachowski et al. analysed aggressive and invasive cell lines and 
identified many mesenchymal markers such as osteonectin/SPARC, plasminogen 
activator inhibitor (PAI)-1, fos-related antigen (FRA)-1, thrombospondin (TSP)-1, 
membrane type-1 metalloprotease (MTI-MMP) and collagens VI, α1 and I, α229. In 2003, 
Jechlinger et al. performed gene expression profiling on EpH4-Ras transformed 
mammary epithelial cells following TGF-β-induced EMT, to reveal a set of genes 
specifically regulated during EMT. These genes included downregulated epithelial 
markers (E-cadherin, keratin 14, occludin, plakophilin-1, thrombospondin-1, p120ctn) 
and upregulated mesenchymal markers (N-cadherin, vimentin, laminin-β-1, decorin, 
osteonectin/SPARC, collagen type VI-α1, tenascins). Other genes were involved in a 
variety of cellular activities such as proteolysis (MMPs, TIMPs, maspin, cathepsins), 
signal transduction (PDGF-α and -β receptors, dual specificity protein phosphatase-1, 
BMP4, Grb7), transcription factors (EGR-1 and -2, Snail, bcl-3) and many others46. In 




carcinomas and identified genes involved in extracellular remodeling and cell adhesion 
(VIM, ADAMT5, HTRA3, SPARC, LUM, THB1 and 2), development (HOXA7, POSTN, 
SFRP2, SFRP4, MSX1), signal transduction (PDGFA, PDGFRA) and many others. 
Specifically, they identified vimentin and osteonectin/SPARC as poor prognostic 
indicators in breast cancer47. 
 
1.2.3 Recent Findings Linking EMT with Basal-like Phenotype in Breast Cancer  
and Cancer Stem Cells 
Recent studies by Perou and Sorlie et al. on gene expression profiling enabled the 
identification of different subgroups of breast tumours with distinct molecular 
signatures48,49. According to this molecular classification, breast carcinomas can be 
divided into at least four biologically different phenotypes: (i) normal-like phenotype, (ii) 
luminal/ER+ phenotype, (iii) ER–/ERBB2 overexpressing phenotype and (iv) basal-like 
phenotype. Basal-like phenotype comprises tumours expressing markers characteristic of 
the myoepithelium of the normal mammary gland. These include expression of p63, 
SMA, calponin, S100 protein, and basal cytokeratins CK 5/6, CK14 and CK17. 
 
Importantly, this molecular classification has significant clinical value because some of 
the molecular phenotypes, in particular basal-like phenotype, show unfavourable 
prognosis and special proclivity for distant metastasis to the lung and brain50. 
Interestingly, a recent study by Sarrio et. al. suggested that EMT in breast cancer relates 




immunohistochemical study on more than 450 breast tumours revealed that upregulation 
of EMT markers (vimentin, smooth muscle actin, N-cadherin and cadherin-11) and 
overexpression of extracellular matrix remodeling proteins (SPARC, laminin and fascin), 
together with reduction of characteristic epithelial markers (E-cadherin and cytokeratins), 
preferentially occur in breast tumours with basal-like phenotype51. Furthermore, they 
suggest that cells with basal-like phenotype may be especially prone to undergoing EMT, 
with breast carcinosarcomas and fibroblastic cancer cell lines being extreme examples of 
this phenotypic plasticity. The tendency of basal-like cells to undergo EMT may be 
related to the high aggressiveness and characteristic metastatic spreading of these 
tumours. 
 
Furthermore, there is now also evidence linking EMT and the stem-cell phenotype. 
During the process of tumour metastasis, which is often enabled by EMT, disseminated 
cancer cells seem to acquire self-renewal capability, similar to that exhibited by stem 
cells, in order to seed distant sites. Cancer stem cells are thought to exhibit a 
CD44high/CD24low antigenic phenotype, highly capable of tumour initiation52.  Mani et al. 
report that the induction of EMT in non-tumorigenic, immortalised human mammary 
epithelial cells (HMECs) by ectopic expression of Twist or Snail, results in the cells 
acquiring fibroblast-like, mesenchymal appearances, coupled with downregulation of 
epithelial markers (such as E-cadherin) and upregulation of mesenchymal markers (such 
as N-cadherin, vimentin and fibronectin). Most fascinatingly, they discovered that most, 
if not all, of the mesenchymal-like cells generated by the induction of EMT, acquired a 




mammary stem cells. Similarly, induction of EMT in HMLEs by exposure to TGF-β1 
resulted in the appearance of mesenchymal-looking cells and acquisition of the 
CD44high/CD24low phenotype. Much like cancer stem cells, these EMT-induced cells 
were able to form mammospheres, soft agar colonies and tumours more efficiently, that is 
to say, have become more tumorigenic. The findings by Mani et al. describe an 
unexpected convergence of two lines of recent research. Stem cells have been 
documented in a variety of normal tissues, and more recently extended to neoplasia53. 
Independent of these discoveries, EMT has been long described as a biological program 
for embryogenesis and in recent years, acquisition of invasiveness in malignant cells54. 
None of these findings hinted a link between these two sets of phenomena until the 
findings of Mani et al. Indeed, the discovery that EMT generates cells with many of the 
properties of self-renewing stem cells holds much promise for the further understanding 












1.2.4 Reconciling the EMT Paradox 
Despite the abundance of evidence for EMT in embryonic development and normal 
histogenic processes, the role of EMT in cancer progression has been the subject of 
controversy and healthy debate14,55 because in most cancers, full EMT – the complete 
loss of epithelial markers and gain of mesenchymal markers – is rarely observed. In fact, 
the presence of certain epithelial markers, such as E-cadherin and cytokeratins, is 
routinely used in diagnostic pathology to determine epithelial cancer subtypes and detect 
metastatic epithelial cancers in patients.  
 
Indeed, the presence of well-differentiated cells with epithelial characteristics within 
invasive and metastatic carcinoma appears to contradict the theory of EMT as a feature in 
tumour invasion and metastasis. However, there are several possible explanations that 
may reconcile this paradox. Firstly, malignant cells may undergo an incomplete EMT56, 
that is, only partial transition to a mesenchymal phenotype. Taking into account that cells 
are continually faced with a myriad of intra- and extra-cellular stimuli at any given time, 
it is likely that response does not result in an all-or-nothing outcome but rather a 
compromise of the push and pull signals. Hence, EMT is likely to manifest in phenotypic 
changes over a broad spectrum, from purely epithelial to purely mesenchymal, with the 
intermediate transition being more of the norm. Secondly, after migrating to secondary 
sites, invasive cells can regain epithelial morphology56, possibly conferring an advantage 
for the establishment of a secondary tumour. This regain of epithelial characteristics 




active invasion have arrested proliferative capacity57. This reversion known as MET, may 
be due to the fact that these cells are no longer receiving the same cytokine signals as 
they did at the primary site. In addition, promoter hypermethylation and demethylation 
can also be influenced by the tumour microenvironment, which may account for some 
changes in gene expression influencing EMT or MET. Lastly, although EMT is an 
interesting mechanism by which cells may invade, it is not the only mechanism. 
Malignant cells need not disseminate only as individual mesenchymal-like cells. Instead, 
they do also migrate in multicellular aggregates with a more epitheloid morphology, in a 
process known as “collective” or “cohort” migration58. In breast tumour cells for 
example, this type of migration is common and can be observed as cells migrating in 
protruding sheets and tubules connected to the primary tumour. Fascinatingly, a recent 
review by Revenu et al. merges these two mechanisms and suggest that cells involved in 
collective migration may be led by leading-edge cells that have undergone a higher 




 Figure 7. Collective migration of epithelial cells with graded EMT. On the left, the 
apico-basally polarised epithelium is highly ordered and static. On the right, two 
individually migrating cells depict the motile, mesenchymal state. In between, a 
theoretical example of collectively migrating cells is represented. The intermediate 
state is controlled by equilibrium between epithelialising and mesenchymalising cues, 
where leading edge cells undergo a higher degree of EMT. The direction of migration 
is depicted (black arrows). Figure and description were modified from Revenu et al. 







Given the plasticity, reversibility and transient nature of EMT, clearly, one of the 
challenges of studying EMT at present is that EMT cannot be followed in time and space 
in human tumours. Currently available experimental approaches to detect EMT in vivo 
are mainly static. Moreover, the diversity of cellular organisation observed in human 
tumours makes it impossible to recognise EMT in vivo without ambiguity25.  Thus, up to 
now, much of the evidence for the association of tumour invasion with EMT comes from 
studies in cancer cell lines and animal models, while the best method to date for studying 
EMT in vivo are by immunohistochemical observations and expression profiling. 
Excitingly, new and powerful tools developed for in vivo imaging are now beginning to 














1.2.5 Clinical Significance of Understanding EMT in Cancer 
Given that the acquisition and initiation of tumour invasion is the first and essential step 
in the metastatic cascade, and that EMT takes place during this period, targeting EMT 
could have a significant impact in preventing invasion and eventual metastasis.   
 
Already, new evidence supporting EMT as a viable target for cancer treatment is 
emerging. For example, in TGF-β-induced EMT, the autocrine PDGF/PDGFR loop is 
activated and elevated. This autocrine signaling cascade is a requirement for the 
metastatic potential of oncogenic mammary epithelial cells. Inhibition of PDGFR 
signaling interferes with EMT and causes apoptosis in mammary carcinoma cell lines. 
Consequently, application of the established cancer drug STI-571 (imatinib or Gleevec®), 
which is a tyrosine kinase inhibitor, was found to prevent metastasis in mice injected with 
EMT-induced mammary carcinoma cells61. As PDGF-α and -β receptors are found to be 
upregulated late in human breast tumours, the study which was done by Jechlinger et al. 
implies a novel application of STI-571 to therapeutically interfere with potential 
metastasis by inhibiting a protein involved in EMT.      
 
Another example of EMT-targeted therapy includes use of the novel proteosome 
inhibitor, NPI-0052. It appears that NPI-0052 is able to downregulate the EMT inducer, 
Snail via NF-κB inhibition. Supression of Snail results in induction of the metastasis 
tumour suppressor/immune surveillance cancer gene, Raf kinase inhibitor protein 




these cells, E-cadherin is reexpressed while vimentin and fibronectin are 
downregulated62. Thus, the regulation of metastasis by inhibiting of EMT has been again 
demonstrated as a viable therapeutic target.  
 
Another reason compelling the need for EMT inhibition is due to the observation that 
EMT contributes to drug resistance. For instance, cells with mesenchymal signature were 
found to be less sensitive to growth inhibition mediated by the small molecule-EGFR-
inhibitor, erlotinib (Tarceva®) and other EGFR inhibitors like gefitinib (Iressa®) and 
cetuximab (Erbitux®). In parallel, gemcitabine (Gemzar®)-resistant pancreatic cells, 
oxaliplatin (Eloxatin®)-resistant colorectal cancer cells, lapatinib (Tyverb®)-resistant 
breast cancer and paclitaxel (Taxol®)-resistant ovarian carcinoma have all been 
associated with EMT63. Therefore, it now becomes extremely crucial to inhibit or reverse 
EMT in order to restore the efficacy of currently available drug therapies.   
 
Lastly, results from a recent study provide supporting evidence that residual breast 
tumour cell populations surviving after conventional chemotherapy may be enriched for 
subpopulations of cells with tumour-initiating and mesenchymal features64.  Thus, 
targeting proteins involved in EMT may provide a therapeutic strategy for eliminating 






1.3 Techniques Employed 
1.3.1 Laser Capture Microdissection (LCM) 
In recent years, the tumour microenvironment, which may consist of stromal cells, 
endothelial cells and inflammatory cells have been increasingly regarded as an important 
facet in tumour development. In addition, the tumour itself is known to be heterogenous 
in nature, which can fortunately be discerned to a certain degree by microscopic 
evaluation. Using this advantage, laser capture microdissection (LCM) is a method to 
procure subpopulations of tissue cells under direct microscopic visualisation to yield 
histologically pure and enriched cell populations, without contamination from 
surrounding cells65,66 (Figure 8). When applied in combination with genomic platforms, 













Figure 8. Principles of laser capture microdissection. (A) The PixCell II Laser 
Capture Microdissection instrument (Arcturus Engineering, USA). The unit above the 
microscope stage houses the infrared laser device. (B) The basic principles of cell 
procurement using laser capture microdissection. Figures were modified from 








1.3.2 RNA Amplification 
The completion of the Human Genome Project has made possible comprehensive 
analysis of genome-wide expression. Expression analysis using microarrays to 
simultaneously quantify expression levels of thousands of genes in a single experiment 
have in recent years become a standard tool for elucidating differences that exist between 
normal and disease tissue and in various cancer cell lines under differing conditions. 
However, the primary limitation to this technology is the requirement for large amounts 
of RNA, in the microgram range, for array hybridisation. Unfortunately, many samples of 
interest such as those obtained from LCM, fine needle aspirates, core needle biopsies, 
primary cultures or cell sorting, can yield only nanogram quantities of RNA, far less than 
the microgram quantities required for most microarray platforms. 
 
For this reason, RNA amplification techniques were developed to expand very small 
quantities of RNA samples to quantities sufficient for microarray application. Studies 
show that amplification of RNA introduces minimal bias and may in fact improve the 
reliability and reproducibility of array results67,68. The principle of the RNA amplification 
procedure lies in the use of a T7 RNA Polymerase to drive transcription of 
complementary DNA (cDNA) derived from total RNA, to generate large amounts of 





Epithelial-mesenchymal transition (EMT) is defined by the loss of epithelial 
characteristics and the acquisition of a mesenchymal phenotype. EMT is thought to occur 
during cancer progression and contribute to the acquisition of invasiveness, which is the 
first and essential step leading to metastasis.  
 
Thus, the objectives of our study are to: 
1. Establish a successful protocol in our laboratory that combines the use of laser 
capture microdissection, RNA amplification and microarray techniques to analyse 
gene expression profiles from discrete subpopulation of cells within histologically 
complex tumour specimens. 
2. Identify EMT-related genes that are differentially expressed in the progression of 
breast cancer. 
3. Determine at which point in breast cancer progression do these EMT-related genes 
first become differentially expressed, that is, during  
• normal (normal breast epithelia) to neoplastic (DCIS) transition, or  
• during pre-invasive (DCIS) to invasive (IDC) transition. 





Materials and Methods 
3. MATERIALS AND METHODS 
3.1 Materials 
The more important reagents and kits used in the study are listed below according to 
manufacturer.  
  
A. Arcturus Engineering (Mountain View, CA, USA) 
• CapSure® Macro LCM Caps (Cat # LCM 0211) 
• PicoPure® RNA Isolation Kit (Cat # KIT 0204) 
 
B. Ambion Inc. (Austin, TX, USA) 
• MessageAmpTM II aRNA Kit (Cat # AM1751) 
• Illumina® TotalPrep RNA Amplification Kit (Cat # AMIL1791) 
 
C. Illumina® Inc. (San Diego, CA, USA) 
• Human Whole-Genome Gene Expression-6 v.2 Beadchips  
(Specific Array ID # 4216765022, 4216765023, 4216765024) 
• Reagents and consumables related to Beadchip processing as per manufacturer’s 
packaging (Cat # 11226030) 
 
D. Promega Corporation (Madison, WI, USA) 
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E. Applied BiosystemsTM (Foster City, CA, USA) 
• TaqMan® Universal PCR Master Mix (Cat # 4304437)  
• TaqMan® Gene Expression Assays 
o CDH2 (Assay ID # Hs00983062_m1) 
o SPARC (Assay ID # Hs00234160_m1) 
o KRT14 (Assay ID # Hs00559328_m1) 
o SERPINB5 (Assay ID # Hs00985283_m1) 
• TaqMan® Endogenous Controls 
o GAPDH (Cat # 4326317E) 
 
F. Dako (Glostrup, Denmark) 
• Target Retrieval Solution, 10X Concentrate (Cat # S1699) 
• Envision+ System-HRP Labeled Polymer, Anti-Mouse (Cat # K4001) 
• Liquid DAB Substrate Chromogen System (Cat # K3466) 
 
Other general reagents were prepared using chemical or molecular grade reagents. All 
buffers and solutions were prepared using Millipore-filtered water. The general chemicals 
that were used in this project are listed according to manufacturers in Appendix A and the 
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3.2 Methods 
3.2.1 Clinical Specimens 
Frozen Specimen 
Samples of tissue from three cases of breast carcinoma were obtained from the NUH-
NUS Tissue Repository, Singapore. The tissues contained mixed neoplastic cell 
populations of ductal carcinoma in-situ (DCIS) and invasive ductal carcinoma (IDC), as 
well as adjacent normal breast ducts. All tumours were Grade 3/3 IDC.  
 
Formalin-fixed, paraffin-embedded (FFPE) Specimen 
Thirty archival formalin-fixed paraffin-embedded tissue blocks were obtained from the 
Department of Pathology, National University Hospital, Singapore. The tissues also 
contained mixed neoplastic populations of DCIS and IDC, as well as adjacent normal 
breast ducts. Clinical characteristics of the specimens are as outlined in Table 2.   
 
All breast tumours and matched normal tissues (frozen and FFPE) were obtained with 
patient consent and complied with the regulations set by the NUS Institutional Review 
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Tumour Size (cm) 
pT1 (≤ 2.0) 
pT2 (2.1-5.0) 
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3.2.2 Laser Capture Microdissection (LCM) 
3.2.2.1 OCT Embeddation of Frozen Tissues for Sectioning 
In a cryostat, each frozen tissue was placed on a metal chuck containing OCT and 
allowed to equilibriate to –25°C and sectioned with the microtome to 8-μm thickness and 
mounted onto non-coated glass slides. The sections were then allowed to dry at room 
temperature for 1 minute before staining.  
 
3.2.2.2 Hematoxylin Staining 
The sections were stained in RNase-free Gill’s III hematoxylin for 30 seconds and 
dehydrated with increasing concentrations of ethanol (70%, 95% and 100%) for 10 
seconds, twice each and lastly with xylene for 2 seconds. The sections were allowed to 
air-dry for 5 minutes before LCM is performed.  
 
3.2.2.3 Performing LCM 
The different tumour subtypes and normal ducts were identified by microscopic 
visualisation following hematoxylin staining. Cells were microdissected using the PixCell 
II LCM System (Arcturus Engineering, Mountain View, CA, USA) with 50, 000 pulses 
corresponding to approximately 30, 000 cells. Each shot had a laser setting of 80 mW 
power and 1 msecond duration to generate a spot size of approximately 8.0 μm. Cells 
were lasered off the slides and onto a LCM collection cap.  
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LCM was performed on three surgically resected human breast cancer specimens that 
contained components of non-malignant breast epithelia, ductal carcinoma in situ (DCIS) 
and invasive ductal carcinoma (IDC) localized within a single histological section. 
 
3.2.3 RNA Extraction 
3.2.3.1 Minimisation of Ribonuclease (RNase) and Genomic DNA Contamination 
Generally, aseptic techniques were maintained at all steps to ensure an RNase-free 
environment. Benchtops and pipettors were cleaned with RNaseZap (Ambion, USA, Cat# 
9780). DNase, RNase and pyrogen-free sterile filter tips and microcentrifuge tubes were 
used. RNA-related work was carried out inside a PCR hood following 10 minutes UV 
illumination of the hood interior. Many of these precautions also reduce the risk of 
contaminating RNA samples with genomic DNA.     
 
3.2.3.2 Isolation of Total RNA  
RNA from the microdissected cells collected in the cap was isolated using the PicoPure® 
RNA Isolation Kit (Arcturus, USA). 50 μl of Extraction Buffer was pipetted into each 0.5 
ml thin-walled microcentrifuge tube and the LCM cap is attached. The cap-
microcentrifuge tube assembly was inverted such that the buffer covers the entire surface 
of the cap and incubated at 42°C for 30 minutes. Following incubation, the cap-tubes 
were centrifuged at 800 g for 2 minutes to collect the cell extracts into the 
microcentrifuge tubes. RNA purification columns in 2 ml microcentrifuge tubes were 
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pre-conditioned with 250 μl Conditioning Buffer for 5 minutes and centrifuged at 16000 
g for 1 minute. The cell extracts were each added with 50 μl 70% ethanol, mixed by 
pipetting and loaded onto the pre-conditioned RNA purification columns. To bind RNA 
to the columns, the tubes were centrifuged at 100 g for 2 minutes, followed by 16000 g 
for 30 seconds to remove flowthrough. 100 μl Wash Buffer 1 was then pipetted onto each 
column and centrifuged at 8000 g for 1 minute. DNA was removed at this point using the 
RNase-free DNase Set (Qiagen, USA, Cat# 79254). 40 μl of DNase incubation mix was 
pipetted directly onto each purification column membrane and incubated at room 
temperature for 15 minutes. 40 μl Wash Buffer 1 was added to each column and 
centrifuged at 8000 g for 15 seconds. 100 ul Wash Buffer 2 was added to each column 
and centrifuged at 8000 g for 1 minute. Another 100 μl Wash Buffer 2 was added to each 
column and centrifuged at 16000 g for 2 minutes. The columns were then transferred to 
new 0.5 ml microcentrifuge tubes and 11 μl of Elution Buffer was pipetted directly onto 
the surface of the column membrane. After 1 minute incubation at room temperature, the 
columns were centrifuged at 1000 g for 1 minute and then at 16000 g for 1 minute. Total 
RNA was always kept on ice when working and any leftover RNA was stored at –80°C.  
 
3.2.3.3 Quantification and Quality Assessment of Purified Total RNA from LCM 
Tissues  
The purified total RNA was quantified using Biophotometer (Eppendorf, Germany) by 
measurement of absorbance values at 260 nm, with the assumption that the optical 
density (OD) of 40 μg/ml single-stranded RNA at 260 nm equals to 1. An OD ratio of 
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260nm/280nm of 1.4 and above was considered acceptable for total RNA isolated from 
LCM tissues. 
 
3.2.4 Amplification of mRNA from Purified Total RNA 
Amplication of mRNA from purified total RNA was carried out with MessageAmpTM II 
aRNA Amplification Kit (Ambion, USA) according to manufacturer’s instructions and 
using enzymes and reagents supplied with the kit. For each series of reaction, a master 
mix containing all reaction components except the template was prepared so as to 
minimise variability and reduce errors. 
 
3.2.4.1 Reverse Transcription to Synthesise First Strand cDNA 
100 ng of total RNA from each sample was added to thin-walled 0.5 ml microcentrifuge 
tubes containing 1 μl of oligo (dT) primer and adjusted to a final volume of 12 μl with 
nuclease-free water. The mixtures were incubated at 70°C for 10 minutes in a thermal 
cycler (GeneAmp® PCR System 9700, Applied Biosystems, USA), centrifuged briefly 
following incubation and placed on ice. Each 20 μl first strand cDNA reaction consisted 
of 2 μl of 10X First Strand Buffer, 4 μl of dNTP (GTP, ATP, CTP and UTP) mix, 1 μl of 
RNase inhibitor and 1 μl of ArrayScript enzyme that is added to the heat-denatured RNA 
template and primer mix. The first strand cDNA mixtures were incubated in an air 
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3.2.4.2 Second Strand cDNA Synthesis 
Each 100 μl second strand cDNA reaction consisted of 63 μl nuclease-free water, 10 μl 
of 10X Second Strand Buffer, 4 μl of dNTP mix, 2 μl DNA polymerase, 1 μl RNase H 
that is added to the first strand cDNA mixture. The second strand cDNA mixtures were 
then incubated in a non-heated lid, thermal cycler at 16°C for 2 hours and placed on ice.  
 
3.2.4.3 cDNA Purification 
250 μl of cDNA Binding Buffer was added to each second strand cDNA mixture, mixed 
thoroughly by pipetting and loaded onto the centre of a cDNA filter cartridge. The tubes 
were centrifuged at 10,000 g for 1 minute and the flowthrough was discarded. 500 μl of 
Wash Buffer was then added to each cDNA filter cartridge and again centrifuged at 
10,000 g for 1 minute. The flowthroughs were discarded and the tubes were centrifuged 
for an additional minute to remove trace amounts of Wash Buffer. After transferring the 
cDNA filter cartridges into a cDNA elution tube, 10 μl of nuclease-free water, preheated 
to 55°C was applied onto the centre of the filter. The tubes were incubated at room 
temperature for 2 minutes, followed by a centrifugation at 10,000 g for 1.5 minutes. The 
cDNA in the filter cartridges were eluted for a second time with another 10 μl of 
nuclease-free water, making the final double-stranded cDNA eluate volume 





Materials and Methods 
3.2.4.4 In Vitro Transcription (IVT) to Synthesise amplified RNA (aRNA) 
Each 40 μl of IVT reaction consisted of 4 μl of T7 ATP solution, 4 μl of T7 CTP 
solution, 4 μl of T7 GTP solution, 4 μl of T7 UTP solution, 4 μl of T7 10X Reaction 
Buffer and 4 μl of T7 enzyme mix that is added to 16 μl of double-stranded cDNA. Once 
assembled, the mixtures were incubated in an air incubator set to 37°C for 14 hours. The 
reactions were stopped by adding 60 μl of nuclease-free water, to produce 100 μl of 
aRNA.  
 
3.2.4.5 aRNA purification 
350 μl of aRNA Binding Buffer was added to each aRNA sample, followed by 250 μl of 
molecular grade 100% ethanol and mixed by pipetting. The mixtures were then loaded 
onto the aRNA filter cartridges, centrifuged at 10,000 g for 1 minute and the flowthrough 
discarded. 650 μl of Wash Buffer was added to each filter cartridge and centrifuged at 
10,000 g for 1 minute.  The flowthroughs were discarded and the tubes were centrifuged 
for an additional minute to remove trace amounts of Wash Buffer. After transferring the 
aRNA filter cartridges into a fresh aRNA elution tube, 100 μl of nuclease-free water, 
preheated to 55°C was applied onto the centre of the filter. The tubes were incubated at 
room temperature for 2 minutes, followed by a centrifugation at 10,000 g for 1.5 minutes. 
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3.2.4.6 Second Round Synthesis of First Strand cDNA 
10 μl of aRNA samples from the first round of amplication was added to thin-walled 0.5 
ml microcentrifuge tubes containing 2 μl of second round primers and adjusted to a final 
volume of 12 μl with nuclease-free water. The mixtures were incubated at 70°C for 10 
minutes in a thermal cycler (GeneAmp® PCR System 9700, Applied Biosystems, USA), 
centrifuged briefly following incubation and placed on ice. Each 20 μl first strand cDNA 
reaction consisted of 2 μl of 10X First Strand Buffer, 4 μl of dNTP mix, 1 μl of RNase 
inhibitor and 1 μl of ArrayScript enzyme that is added to the heat-denatured aRNA 
template and primer mix. The first strand cDNA mixtures were incubated in an air 
incubator set to 42°C for 2 hours and placed on ice. 1μl of RNase H was added to each 
reaction and incubated at 37°C for 30 minutes in an air incubator.  
 
3.2.4.7 Second Round Synthesis of Second Strand cDNA 
To each cDNA sample, 5 μl of T7 oligo (dT) primer was added and incubated at 70°C for 
10 minutes in a thermal cycler (GeneAmp® PCR System 9700, Applied Biosystems, 
USA). The reactions were placed on ice briefly before adding subsequent reagents. Each 
100 μl second strand cDNA reaction consisted of 58 μl nuclease-free water, 10 μl of 10X 
Second Strand Buffer, 4 μl of dNTP mix and 2 μl DNA polymerase that is added to the 
first strand cDNA mixture. The second strand cDNA mixtures were then incubated in a 
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3.2.5 Generation of Biotinylated cRNA for Hybridisation with Illumina® Beadchip 
Arrays 
Generation of biotinylated cRNA for hybridisation with Illumina® Beadchip arrays was 
carried out with Illumina® TotalPrep RNA Amplication Kit (Ambion, USA) according to 
manufacturer’s instructions and using enzymes and reagents supplied with the kit. For 
each series of reactions, a master mix containing all reaction components, except the 
template, was prepared so as to minimise variability and reduce errors. 
 
3.2.5.1 cDNA Purification 
250 μl of cDNA Binding Buffer was added to each second round, second strand cDNA 
mixture, mixed thoroughly by pipetting and loaded onto the centre of a cDNA filter 
cartridge. The tubes were centrifuged at 10,000 g for 1 minute and the flowthrough was 
discarded. 500 μl of Wash Buffer was then added to each cDNA filter cartridge and again 
centrifuged at 10,000 g for 1 minute. The flowthroughs were discarded and the tubes 
were centrifuged for an additional minute to remove trace amounts of Wash Buffer. After 
transferring the cDNA filter cartridges into a cDNA elution tube, 10 μl of nuclease-free 
water, preheated to 55°C was applied onto the centre of the filter. The tubes were 
incubated at room temperature for 2 minutes, followed by a centrifugation at 10,000 g for 
1.5 minutes. The cDNA in the filter cartridges were eluted for a second time with an 
additional 9 μl of nuclease-free water, making the final double-stranded cDNA eluate 
volume approximately 17.5 μl.  
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3.2.5.2 In Vitro Transcription (IVT) to Synthesise cRNA 
Each 25 μl of IVT reaction consisted of 2.5 μl of Biotin-NTP mix, 4 μl of T7 10X 
Reaction Buffer and 2.5 μl of T7 enzyme mix that is added to 17.5 μl of double-stranded 
cDNA. The mixtures were incubated in an air incubator set to 37°C for 14 hours. The 
reactions were stopped by adding 75 μl of nuclease-free water, to produce 100 μl of 
biotinylated cRNA.  
 
3.2.5.3 Biotinylated cRNA purification 
350 μl of cRNA Binding Buffer was added to each cRNA sample, followed by 250 μl of 
molecular grade 100% ethanol and mixed by pipetting. The mixtures were then loaded 
onto the cRNA filter cartridges, centrifuged at 10,000 g for 1 minute and the flowthrough 
discarded. 650 μl of Wash Buffer was added to each filter cartridge and centrifuged at 
10,000 g for 1 minute.  The flowthroughs were discarded and the tubes were centrifuged 
for an additional minute to remove trace amounts of Wash Buffer. After transferring the 
cRNA filter cartridges into fresh cRNA elution tubes, 100 μl of nuclease-free water, 
preheated to 55°C was applied onto the centre of the filter. The tubes were incubated at 
room temperature for 2 minutes, followed by a centrifugation at 10,000 g for 1.5 minutes. 
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3.2.5.4 Quantification and Quality Assessment of Purified Biotinylated cRNA  
The purified biotinylated cRNA were quantified using a Biophotometer (Eppendorf, 
Germany by measurement of absorbance values at 260 nm, with the assumption that the 
optical density (OD) of 40 μg/ml single-stranded RNA at 260 nm equals to 1. An OD 
ratio of 260nm/280nm of 2.0 and above was considered good for downstream 
applications, that is, for Illumina® Beadchip Arrays and Quantitative Real-Time PCR 
(QRT-PCR).  
 
3.2.6 Illumina Beadchip 
Whole genome expression profiling was carried out using Illumina® Beadchip Arrays, 
specifically the Human Whole Genome Gene Expression-6 v2.0 Beadchips (from here 
onwards referred to as Beadchips or microarray). The experiments were performed as per 
manufacturer’s instructions, using reagents supplied with the Beadchips.  
 
3.2.6.1 Hybridisation of Samples onto Beadchips 
1500 ng of biotinylated cRNA in a total volume of 10 μl was prepared from each sample 
for hybridisation. After adding 20 μl of HYB to each cRNA sample, the samples were 
preheated at 65°C for 5 minutes and allowed to cool to room temperature. The Beadchips 
were loaded onto the Hyb Chamber containing 200 μl HCB in the buffer reservoir, and 
the samples were dispensed into the sample port and allowed to distribute by capillary 
action to cover the arrays on the Beadchips. The Hyb Chamber lid was then carefully 
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sealed and Beadchips within the Hyb Chamber was incubated in an oven (brand) at 58°C 
for 17 hours, with rocker speed set to 5.  
 
3.2.6.2 Washing and Staining of Beadchips 
Following incubation, the Hyb Chamber was removed from the oven and disassembled. 
The Beadchips were removed and submerged face up in a Pyrex No. 3140 beaker 
containing 1 L Wash E1BC solution. After carefully removing the coverseals from the 
Beadchips, the Beadchips were loaded onto a slide rack submerged in a staining dish 
containing 250 ml Wash E1BC solution. The slide rack holding the Beadchips was then 
transferred into a Hybex Waterbath containing High-Temp Wash Buffer, prewarmed 
overnight to 55°C, and incubated for 10 minutes. After incubation, the slide rack was 
transferred back to the staining dish, now containing a fresh 250 ml Wash E1BC solution. 
The dish and rack were placed on an orbital shaker set to 110 rpm for 5 minutes. The 
slide rack was then transferred to a clean staining dish containing 250 ml 100% ethanol, 
and again placed on an orbital shaker set to 110 rpm for 10 minutes. Following the 
ethanol wash, the rack was transferred to a staining dish containing fresh 250 ml Wash 
E1BC solution, and placed on an orbital shaker set to 110 rpm for 2 minutes. The 
Beadchips was then removed from the slide rack and transferred to wash trays containing 
4 ml of Block E1 buffer and set on a rocker at medium speed for 10 minutes.  2 ml of 1 
μg/ml Streptavidin-Cy3 was added to fresh wash trays to which the Beadchips were then 
transferred to, and set on a rocker at medium speed for 10 minutes, protected from light. 
For the last wash, the Beadchips were again loaded onto a slide rack and submerged in a 
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staining dish containing fresh 250 ml Wash E1BC solution, placed on orbital shaker set 
to 110 rpm for a further 5 minutes. Finally, the Beadchips were dried by centrifugation at 
500 g (check with BSF) for 5 minutes and scanned using the Illumina BeadStation.  
 
3.2.6.3 Scanning and Data Acquisition from Beadchips using Illumina BeadStudio 
The Beadchips were scanned using the Illumina BeadStation and data was acquired and 
analysed using the Illumina BeadStudio software. Data from the gene probes was filtered 
for signals were significantly higher (p<0.05) than the background signals. Fold changes 
were calculated by comparing normal epithelia to matched DCIS as well as DCIS to 
matched IDC, in each case, to reveal genes that are differentially expressed as cells 
transition from normal to pre-invasive (DCIS), and from pre-invasive to an invasive state 
(IDC). Genes were scored as upregulated if the fold changes were positive and 
downregulated if the fold changes were negative. Genes for further analysis were 
shortlisted as genes that had a fold change that was greater than 1.5, concordant in all 3 
samples. The candidate genes were further shortlisted by selecting for reported EMT-
related genes, according to multiple published reports17,29,46,47,51,70. Lastly, the shortlist of 







Materials and Methods 
3.2.7 Validation by Quantitative Real-time PCR (QRT-PCR) 
3.2.7.1 cDNA Synthesis 
cDNA was synthesised from cRNA from LCM tissues and from breast cancer cell lines 
using ImProm-IITM Reverse Transcriptase (Promega, USA). 1 μg RNA was converted per 
20 μl reaction. For each 20 μl reverse-transcription (RT) reaction, 1 μg of RNA template 
was combined with 0.5 μg oligo (dT)15 primer to a volume of 5 μl and incubated at 70°C 
in a heated-lid thermal cycler (GeneAmp® PCR System 9700, Applied Biosystems, USA) 
for 5 minutes. The heat-denatured RNA template and primer mix was then quick-chilled 
at in an ice-water bath for 5 minutes. For each series of RT reaction, a master mix 
containing all reaction components except the template RNA was prepared so as to 
minimise variability and reduce errors. The final composition of each 20 μl RT reaction 
included 1X ImProm-IITM Reaction Buffer, 3 mM MgCl2, 10 mM of each dNTP (GTP, 
ATP, CTP and UTP), 40 units (1 μl) recombinant RNasin® ribonuclease inhibitor, 40 
units (1 μl) ImProm-IITM Reverse Transcriptase enzyme, 5 μl of the heat-denatured RNA 
template and primer mix and RNase-free water to a final volume of 20 μl. The RT 
reaction was performed in a heated-lid, thermal-cycler (Mastercycler epgradient S, 
Eppendorf, Germany) set to cycle as follows: annealing at 25°C for 5 minutes, extension 
of first strand cDNA at 42°C for 60 minutes and heat-inactivation of the ImProm-IITM 
Reverse Transcriptase enzyme at 70°C for 15 minutes. The synthesised cDNA was stored 
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3.2.7.2 Qualitative Real-time PCR (QRT-PCR) using Applied BiosystemsTM (ABI) 
TaqMan® Gene Expression Assays 
For each series of QRT-PCR, a master mix containing all reaction components except the 
template RNA was prepared so as to minimise variability and reduce errors. The final 
composition of each QRT-PCR included 1X Taqman® Universal PCR Master Mix, 0.2 
μM TaqMan® Expression Assay containing primer and probe for gene of interest, 0.1 μM 
TaqMan® Endogenous Control containing primer and probe for housekeeping gene 
GAPDH, 0.1 μl cDNA template and distilled water to a final volume of 10 μl. The QRT-
PCR was performed in a thermal cycler (7500 Standard Real-time PCR Machine, 
Applied Biosystems, USA) set to cycle as follows: activation at 50°C for 2 minutes, Taq 
activation at 95°C for 10 minutes, 40 cycles of denaturation at 95°C for 15 seconds, 
annealing at 59°C for 30 seconds and extension at 68°C for 35 seconds. Fluorescence 
detection of FAM signals for gene of interest and VIC signals for housekeeping gene was 
carried out at the extension step at every cycle. Each reaction was carried out in 
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 Table 3. ABI TaqMan® Gene Expression Assays and Endogenous Control 
Gene Accession Number Assay ID Detector 
Amplicon Size 
(bp) 
GAPDH NM_002046.3 4326317E VIC 122 
CDH2 NM_001792.3 Hs00983062_m1 FAM 78 
SPARC NM_003118.2 Hs00234160_m1 FAM 76 
KRT14 NM_000526.4 Hs00559328_m1 FAM 65 
SERPINB5 NM_002639.4 Hs00985283_m1 FAM 82 
 
 
3.2.7.3 Analysis of QRT-PCR Results 
Quantitative values were obtained from the threshold cycle number (Ct) and the fold-
change in expression was calculated using the ΔΔCt method. Target genes measurements 
in all samples were normalised to the housekeeping gene, GAPDH. Data is presented as 
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3.2.8 Immunohistochemistry (IHC)  
3.2.8.1 Deparaffinisation and Rehydration of Tissue Sections 
Immunohistochemical detection of the antigen of interest was performed on formalin-
fixed paraffin-embedded tissue acquired from the Department of Pathology archive. 
Using standard microtoming procedures, 4 μm tissue sections were cut and mounted onto 
Superfrost®/Plus positively-charged slides (Fisherbrand®, Fisher Scientific, USA). The 
sections were air-dried overnight and then heated at 60°C for 2 hours on a hot plate. The 
sections were allowed to cool for 15 minutes to room temperature before continuing. 
Sections were deparaffinised with three changes of xylene, 5 minutes each, followed by 
rehydration in a series of graded ethanols (100%, 95% and 70%), 10 seconds each, and 
lastly in a water bath for 2 minutes.  
 
3.2.8.2 Antigen Retrieval and Blocking of Endogenous Peroxidase Activity 
Prior to incubation with primary antibody, the sections were subjected to various heat-
induced epitope retrieval (HIER) pre-treatments, depending on the antigen of interest, 
details of which are summarised in Table 4A. The citrate buffer used in the protocol was 
purchased from Dako, USA while the Tris-EDTA buffer was prepared in the laboratory 
from basic chemicals. Following HIER pre-treatment, endogenous peroxidase activity in 
the tissue sections was blocked using 3% hydrogen peroxide (H2O2) in phosphate-
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3.2.8.3 Immunostaining and Visualisation 
Primary antibodies used in the IHC, dilution factors and their incubation times are listed 
in Table 4B. Primary antibodies were diluted to the appropriate concentration with PBS, 
containing 0.1% bovine serum albumin (BSA) and 0.01% sodium azide. Negative 
controls were employed in every batch of immunostaining, whereby the primary antibody 
is substituted with PBS diluent. HIER pre-treatment and immunostaining for all 30 cases 
were always carried out in a single batch to ensure uniformity in processing.  
 
Detection was carried out using an anti-mouse HRP-conjugated secondary antibody 
(Dako, USA) at room temperature for 30 minutes. Chromogenic visualisation was 
achieved by applying 3’3’-diaminobenzidine (DAB)-substrate chromogen solution 
(Dako, USA) for 5 minutes. Colour development at the end of 5 minutes was stopped by 
washing in Millipore water. The sections were counterstained with Gill’s III Hematoxylin 
for 30 seconds, dehydrated by a series of graded alcohols (70%, 95% and 100%) and 
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Heat source Buffer Duration 
N-cadherin Pressure cooker Tris-EDTA Buffer, pH 9.0 30 min 
SPARC Microwave Citrate Buffer, pH 6.1 (Dako) 12 min 
Keratin 14 Pressure cooker Citrate Buffer, pH 6.1 (Dako) 20 min 




















(Clone 6G11, Cat# M3613) 
Mouse 
monoclonal 
1:50 4°C overnight 
SPARC 
Santa Cruz 
(Clone AON-5031, Cat# sc-73472)
Mouse 
polyclonal 
1:100 4°C overnight 
Keratin 14 
Neomarkers 









(Clone G167-70, Cat# 554292) 
Mouse 
monoclonal 
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3.2.8.4 Assessment of Staining and Scoring 
The immunohistochemical technique used in this study imparts an insoluble dark brown 
stain of DAB precipitate, revealing antibody-bound antigenic sites on the cells. The 
staining intensity, percentage of positive cells and profiles were scored by a pathologist in 
a blind manner. In addition, all the sections were examined without prior knowledge of 
clinical information for any of the cases. The staining intensity was given the scores: 0, 
no staining; 1, weak staining; 2, moderate staining and 3, strong staining. The cut-off 
threshold for a positive call is if more than 10% of cells stain positively for the antigen. In 
all cases, the score given by the largest percentage of cells is taken.    
 
3.2.8.5 Statistical Analysis 
Chi-square tests (χ2) were used to compare the expression of N-cadherin, SPARC, keratin 
14 and maspin between normal, DCIS and IDC samples. Chi-square tests were also used 
to evaluate the relationship between expression of the various antigens and the age of 
patients, tumour grade, tumour size, lymph node status and presence of lympovascular 
invasion. Significance was determined as p-value less than 0.05. The chi-square tests 
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4. RESULTS AND DISCUSSION 
The strategy we chose to employ in our study was to use a microarray approach to 
identify EMT-related genes involved in breast tumour progression, which we could then 
further investigate. Taking into consideration the difficulty and cost of the technique, we 
decided to perform LCM-coupled microarray analysis only on a small number of cases 
(n=3), while ensuring that we validate our findings by performing IHC on selected 
candidates of interest on a larger number of cases (n=30) to achieve statistical 
significance. 
 
4.1 LCM Results 
Three surgically resected human breast cancer specimens that contained components of 
non-malignant ducts, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma 
(IDC) localised within a single histological section were chosen. Figure 9 shows 
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 Before After Captured Figure 9. Representative 
LCM procurement of 
normal breast epithelia, 
DCIS and IDC. 
Phenotypically normal 
breast epithelium and 
tumour cells from DCIS 
and IDC within a single 
histological section were 
captured, leaving behind 
stromal cells. Sections 
were 8-μm thick and 
stained with H&E, 
without coverslipping. 
Images before capture, 
after capture and captured 





   
DCIS 
   
IDC 




Results and Discussion 
4.2 Quantity and Quality of RNA Extracted from LCM 
Quantity and quality of RNA extracted was measured using the BioPhotometer 
(Eppendorf AG, Hamburg, Germany). Typically around 100-300 ng of RNA was 
obtained from a total of 50,000 laser pulses with a spot size of 8-μm per pulse, 
corresponding to approximately 30,000 cells. 2-rounds of amplification by IVT generally 
yielded 70-80 μg of amplified RNA, representing an approximate 400-fold amplification 
(Figure 10A).  
 
The quality of RNA was estimated by the ratio of absorbance at 260 nm over 280 nm, 
known as optical density (OD). RNA from LCM material had OD measuring between 1.5 
and 1.9. An OD of more than 1.4 was considered to be acceptable for tissues obtained 
from LCM methods. The quality of RNA improved after 2-rounds of amplification, to an 















Total RNA yield extracted 
from LCM samples
cRNA after 2-rounds of 
amplification by IVT
RNA Quantity (ug) 0.19 79.23














































Figure 10. RNA quantity and quality extracted from LCM samples and after 2-
rounds of amplification by IVT. (A) Amplification yielded an approximate 400-fold 
increase in RNA quantity. RNA quantity after amplification is between 70-80 μg, 
from a starting quantity of 100-300 ng. Average RNA concentration after 
amplification is approximately 980 ng/μl. (B) RNA quality measured by OD ratio of 
Absorbance at 260/280 nm, increased from an average of 1.69 to 2.24, indicating a 
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4.3 Gene Expression Results 
4.3.1 Overview of Transcriptomic Changes at Different Phases of Progression 
The Illumina Beadchip contained probes for 48,701 genes. Genes of interest were 
shortlisted as those that showed a concordant up- or down-regulation in all 3 cases, 
resulting in a list of 1439 genes. Of those, 1211 genes had altered expressions at the 
normal to DCIS transition while 228 genes were altered at the DCIS to IDC transition. 
More specifically, 816 genes were upregulated and 395 downregulated at the normal to 
DCIS transition, while 219 genes were upregulated and 9 downregulated at the DCIS to 
IDC transition (Figure 11).    
 
Interestingly, we noted that the most dramatic transcriptomic change occurs at the earliest 
stages of tumour progression, that is, at the normal to DCIS transition as cells transform 
from a normal to neoplastic state, agreeing with current understanding of breast 
tumorigenesis71,72. However, some gene expression changes were found to occur later in 
breast cancer progression, at the DCIS to IDC transition, either as the cause or as a result 













































Figure 11. Overview of Transcriptomic Change. (A) Out of 48701 genes, 47262 
genes were found to have no significant fold change, while 1439 genes showed a 
concurrent fold change of more than 1.5 in all 3 samples. Of those, 1211 were 
differentially expressed at the normal to DCIS transition while the remaining 228 
genes were differentially expressed at the DCIS to IDC transition. (B) The specific 
number of genes up- or down-regulated at the normal to DCIS transition and at the 
DCIS to IDC transition is shown. More genes underwent changes in expression at the 
early stage of tumour progression (normal to DCIS) than late (DCIS to IDC). 
  54 
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4.3.2 Functional Grouping of Differentially Expressed Genes 
Functional grouping of the differentially expressed genes according to Gene Ontology 
annotations were carried out to permit understanding of their roles in the progression of 
breast cancer. At the normal to DCIS transition, of the 1211 genes that were differentially 
expressed, a significant number of genes were involved in the regulation of transcription 
(221 genes, 18%), signal transduction (175 genes, 14%) and protein metabolism and 
modification (190 genes, 16%).  Other genes included those that participate in cell cycle 
(105 genes, 9%), cell proliferation and differentiation (70 genes, 6%), DNA repair and 
replication (38 genes, 3%), apoptosis (31 genes, 3%), transport (87 genes, 7%), immunity 
and defense (67 genes, 6%) and cellular metabolism (46 genes, 4%). Additionally, a 
significant number of these genes encode for proteins important in cell adhesion (36 
genes, 3%), cell structure and motility (83 genes, 7%) and proteolysis (54 genes, 5%), 
highlighting the important changes in cellular phenotype and microenvironment (Figure 
12).  Of the 228 differentially expressed genes at the DCIS to IDC transition, the majority 
of genes were involved in signal transduction (60 genes, 26%), immunity and defense (41 
genes, 18%), protein metabolism and modification (24 genes, 11%) and in the regulation 
of transcription (21 genes, 9%). Other genes were involved in transport (13 genes, 6%), 
cellular metabolism (7 genes, 3%), cell cycle (8 genes, 4%), cell proliferation and 
differentiation (20 genes, 9%) and apoptosis (5 genes, 2%). Again, a significant number 
of genes had roles in cell adhesion (24 genes, 11%), cell structure and motility (30 genes, 





















Figure 12.  Functional grouping of genes differentially expressed at the normal to DCIS transition. 1211 genes were analysed; 
816 upregulated, 395 downregulated. The categories with the largest number of altered genes were those involving regulation of 
transcription, signal transduction and protein metabolism and modification. (NB. Given that many genes have more than one function, 
some genes may be counted for in multiple categories of function. Genes that have no known biological function were excluded from 
our analysis) 
















Proteolysis Regulation of transcription
Signal 
transduction Transport
N-DCIS Upregulated 17 12 92 43 43 36 32 29 137 30 174 69 58






































Figure 13.  Functional grouping of genes differentially expressed at DCIS to IDC transition. 228 genes were analysed; 219 
upregulated, 9 downregulated. The categories with the largest number of altered genes were those involving signal transduction, 
regulation of transcription and immunity and defense. (NB. Given that many genes have more than one function, some genes may be 
counted for in multiple categories of function. Genes that have no known biological function were excluded from our analysis)  
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transduction Transport
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4.3.3 Expression of EMT-related Genes at Different Phases of Progression 
Additionally, we further shortlisted our genes to those that have been previously reported 
to be related to EMT17,29,46,47,51,70 and found that of the 1439 genes with altered 
expression, there were a total of 65 EMT-related genes. 36 were altered at the normal to 
































Figure 14.  Overview of the number of EMT-related genes identified to be 
differentially expressed. (A) Of 1439 genes identified to have more than 1.5 fold 
change, 65 were identified to be EMT-related genes. Of those, 36 were differentially 
expressed at the normal to DCIS transition and 29 at the DCIS to IDC transition. (B) 














Results and Discussion 
Interestingly, we noted that changes related to EMT took place as early as at the normal 
to DCIS transition and are not necessarily confined to the later stages of tumour 
progression. Indeed, there appeared to be more EMT-related gene expression changes  at 
the normal to DCIS transition (36 genes; 15 upregulated, 21 downregulated) than at the 
DCIS to IDC transition (29 genes, all upregulated). Hence, our data suggests that EMT is 
a multi-step event, occurring first in the early stage of neoplastic transformation and 
further accumulating as the cancer progresses from in situ to invasive. These events 
culminate in the acquisition of a motile, invasive phenotype by the tumour cells, thus 
increasing feasibility of distant metastasis.  
 
Guided by Gene Ontology annotations, the 65 EMT-related genes were categorised into 7 
biological processes: (i) cell adhesion, extracellular matrix, structure and motility, (ii) 
proteolysis, (iii) immunity and inflammation, (iv) metabolism and transport, (v) cell 
proliferation and differentiation, (vi) signal transduction and cell communication and (vii) 
regulation of transcription. Figure 15 illustrates that the three largest clusters were genes 
involved in cell adhesion, extracellular matrix, structure and motility, in proteolysis and 
in signal transduction and cell communication during normal to DCIS transition as well 
as during DCIS to IDC transition. The other clusters of genes were variously involved in 
immunity and inflammation, metabolism and transport, cell proliferation and 
differentiation and regulation of transcription. The list of the 65 EMT-related genes, their 
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Figure 15. Functional grouping of EMT-related genes differentially expressed at 
the normal to DCIS transition (A) and DCIS to IDC transition (B). Genes were 
categorised according to their Gene Ontology annotations to assess the relative 
contribution of each functional group in the progression of breast cancer. Genes 
involved in cell adhesion, proteolysis and signal transduction is key in EMT in breast 
cancer progression. The functional groups are colour coded and the numbers denote 







Results and Discussion 
Table 5. EMT-related Genes Differentially Expressed in at the Normal to DCIS transition. 




Symbol Gene Name Description/Function 
Expression Fold Change 
(Normal vs DCIS) 
Case 1 Case 2 Case 3 
Cell Adhesion, Extracellular Matrix, Structure & Motility (mesenchymal markers) 
10109 ARPC2 Actin related 
protein 2/3 
complex, subunit 
2, 34 kDa 













3925 STMN1 Stathmin1 
/Oncoprotein 18 
Regulation of microtubule (MT) filament 
system by destabilizing microtubules, prevents 
assembly and promotes disassembly of 
microtubules 
1.69 7.46 4.56 
Proteolysis 
1509 CTSD Cathepsin D 
(lysosomal aspartyl 
peptidase) 
Acid protease active in intracellular protein 
breakdown, involved in the pathogenesis of 
breast cancer 
3.34 1.53 3.17 






Bifunctional enzyme with 
methylenetetrahydrofolate dehydrogenase and 
methenyltetrahydrofolate cyclohydrolase 
activities 
3.38 7.11 4.14 

























ABC full transporter, member of the MRP 
subfamily involved in multi-drug resistance 
3.70 1.63 5.63 
Cell Proliferation & Differentiation 
10617 STAMBP STAM binding 
protein (AMSH) 
Ubiquitin-protein or polyubiquitin hydrolase, 
signal transduction for cell growth and MYC 
induction mediated by IL-2 and GM-CSF, 
potentiates BMP signaling by antagonizing the 
inhibitory action of SMAD6 and SMAD7 
2.41 1.78 2.63 




Cell proliferation, spatially regulating 
contractile activity of myosin II during 
cytokinesis, overexpression associated with 
pulmonary carcinogenesis 
1.97 11.73 3.65 
Regulation of Transcription 




Binds single-stranded RNA, influence pre-
mRNA processing and other aspects of mRNA 
metabolism and transport, downregulates E-
cadherin expression 
2.22 2.06 6.94 
3217 HOXB7 Homeo box B7 Transcription factor involved in cell 
proliferation and differentiation, 
overexpression leads to EMT in epithelial 
cells, accompanied by aggressive properties of 
tumorigenicity, migration and invasion, 
downregulates E-cadherin expression 
2.06 7.20 5.12 
602 BCL3 B-cell CLL/ 
lymphoma 3 
Transcriptional activating factor, proto-
oncogene candidate 
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Cell motility, cellular transformation and 
metastasis formation, and in regulating ERK 
activity 
 
2.34 2.69 9.30 
5050 PAFAH1B3 Platlet-activating 
factor 
acetylhydrolase, 
isoform 1b, gamma 
subunit 29kDA 
Inactivates PAH, brain development 2.04 2.28 3.71 
6282 S100A11 S100 calcium 
binding protein 
A11 (calgizzarin) 
Cell cycle progression, differentiation, 
motility, invasion and tubulin polymerization, 
altered expression implicated in tumor 
metastasis 
2.46 4.42 2.28 




Kinase involved in spindle checkpoint 
function, expression is associated with 
cells/tissues with a high mitotic index, 
mutations associated with aneuploidy and 
cancer 
1.66 4.43 3.37 
Cell Adhesion, Extracellular Matrix, Structure & Motility (epithelial markers) 
 
9073 CLDN8 Claudin 8 Tight junction associated protein, Ca2+ 
dependent cell adhesion, downregulated in 
EMT, associated with tumorigenesis in 
colorectal cancer 
-2.08 -1.80 -3.40 




Tight junction associated protein, Ca2+ 
dependent cell adhesion, downregulated in 
EMT 






















149461 CLDN19 Claudin 19 Transmembrane tight junction associated 
protein, Ca2+ independent cell adhesion, 
downregulated in EMT 
-1.65 -1.58 -1.53 
1500 CTNND1 Catenin (cadherin-
associated protein) 
delta 1 (p120ctn) 
Associates in a multiprotein cell-cell adhesion 
complex that also contains E-cadherin, α-
catenin, β-catenin and γ-catenin, involved in 
cell transformation by SRC and in ligand-
induced receptor signaling through the EGF, 
PDGF, CSF-1 and ERBB2 receptors, loss of 
expression estimated in 10% IDCs 
-2.21 -1.76 -3.66 
3852 KRT5 Keratin 5 Intermediate filament, associates with keratin 
14 to form the cytoskeleton of epithelial cells,  
mutations associated with epidermolysis 
bullosa simplex, loss is associated with 
features of aggressive tumours 
-21.46 -5.17 -2.00 
3861 KRT14 Keratin 14 Intermediate filament, associates with keratin 
5 to form the cytoskeleton of epithelial cells, 
mutations associated with epidermolysis 
bullosa simplex 
-26.73 -5.59 -4.31 
3914 LAMB3 Laminin, beta 3 Mediate the attachment, migration and 
organization of cells into tissues during 
embryonic development by interacting with 
other extracellular matrix components, anti-
invasive, anti-proliferative 
-41.45 -4.58 -2.50 
5317 PKP1 Plakophilin 1 Links cadherins to intermediate filaments in 
the cytoskeleton, molecular recruitment and 
stabilization during desmosome formation, 
loss of expression may contribute to invasive 
phenotype in HNSCC 






















800 CALD1 Caldesmon 1     
(H-CAD) 
Regulation of the actin cytoskeleton and cell 
migration, suppresses cancer invasion by 
regulating podosome/invadopodium 
formation, mitosis 
-12.64 -2.05 -8.20 
Proteolysis 







Neutral endopeptidase, inactivates several 
peptide hormones including glucagon, 
enkephalins, substance P, neurotensin, 
oxytocin, and bradykinin, role in tumour 
invasion and facilitating metastasis 
 
-4.80 -3.68 -3.57 
5268 SERPINB5 Serpin peptidase 




Tumor suppressor, prevents growth, invasion, 
and metastatic properties of mammary tumors 
-3.74 -1.55 -1.77 






Protease inhibitor, regulates the tissue factor 
(TF)-dependent pathway of blood coagulation, 
antithrombotic, associate with lipoproteins in 
plasma 
-20.22 -3.78 -4.59 
Metabolism & Transport 




Monooxygenase which catalyze reactions in 
drug metabolism and synthesis of cholesterol, 
steroids and other lipids, key role in retinoic 
acid metabolism 






















762 CA4 Carbonic Anydrase 
IV 
Belongs to family of zinc metalloenzymes that 
catalyze the reversible hydration of carbon 
dioxide, stimulate the sodium/bicarbonate 
transporter activity of SLC4A4 
-1.56 -3.96 -1.72 
Regulation of Transcription 
11278 KLF12 Kruppel-like factor 
12 
Strong transcriptional repression to AP-2-
alpha gene, regulate gene expression during 
vertebrate development and carcinogenesis 
-2.35 -1.60 -2.43 
1958 EGR1 Early growth 
response 1    
(Krox-24) 
Transcriptional regulator induced by TGF-β, 
activates the transcription of target genes 
whose products are required for mitogenesis 
and differentiation, downregulated in cancer 
-29.92 -2.48 -4.31 
1959 EGR2 Early growth 
response 2    
(Krox-20) 
Transcription factor, binds to promoter of 
HOXA4, downregulated in cancer 
-22.68 -5.02 -4.13 
Signal Transduction, Cell Communication 
1843 DUSP1 Dual specificity 
phosphatase 1 
Dephosphorylates MAP kinase ERK2, cellular 
response to oxidative/heat stress, 
downregulation associated with advanced 
stages of epithelial ovarian neoplasms 
-3.39 -1.89 -4.33 
1848 DUSP6 Dual specificity 
phosphatase 6 
Candidate tumour suppressor, negatively 
regulate MAP kinase superfamily 
(MAPK/ERK, SAPK/JNK, p38) which are 
associated with cellular proliferation and 
differentiation 






















2487 FRZB Frizzled-related 
protein (SFRP3) 
Antagonist of Wnt signaling, reduce cellular 
motility, invasion and tumour growth, 
expression associates with up-regulation of 
epithelial markers (i.e., keratins 8 and 18) and 
down-regulation of mesenchymal markers 
(i.e., vimentin, N-cadherin, fibronectin, Slug, 
and Twist) 





Signal transduction, forms p85/p110 complex 
during insulin stimulation leading to increased 
cell migration, role in maintaining tissue 
polarity, disruption associated with malignant 
breast tumour phenotype 
-2.30 -6.24 -1.80 
7048 TGFBR2 Transforming 
growth factor, beta 
receptor II,     
70/80 kDa 
Receptor for TGF-β, activates SMAD 
transcriptional regulators, tumour suppressor, 
decreased expression occurs frequently both in 
early and advanced breast cancer, inactivation 
contributes to tumour metastasis 
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Table 6. EMT-related Genes Differentially Expressed at the DCIS to IDC transition 




Symbol Gene Name Description 
Expression Fold Change 
(DCIS vs IDC) 
Case 1 Case 2 Case 3
Cell Adhesion, Extracellular Matrix, Structure & Motility (mesenchymal markers) 




Homophilic Ca2+ adhesion protein, cell 
motility 













1009 CDH11 Cadherin 11, type 
2, OB-cadherin 
(osteoblast) 
Ca2+ dependent adhesion proteins, 
upregulated during differentiation, role in 
bone development and maintanence, 
implicated in epithelial mesenchymal 
transition 
6.92 3.91 3.56 
1281 COL3A1 Collagen, type III, 
alpha 1 
ECM component, fibrillar collagen usually 
found in extensible connective tissue, 
mesenchymal marker 
9.50 2.47 4.68 
1291 COL6A1 Collagen, type VI, 
alpha 1 
ECM component, cell adhesion, mesenchymal 
marker 
3.67 1.78 4.30 
1292 COL6A2 Collagen, type VI, 
alpha 2 
ECM component, cell adhesion, mesenchymal 
marker 
1.88 1.77 3.03 
1462 CSPG2 Chondroitin sulfate 
proteoglycan 2 
(versican) 
Role in intercellular signaling and in 
connecting cells with the extracellular matrix, 
regulation of cell motility, growth and 
differentiation 
11.26 2.48 4.49 
1634 DCN Decorin (PG-S2) Matrix proteoglycan, binds to type I and type 
II collagen, fibronectin and TGF-β 




















3912 LAMB1 Laminin, beta 1 Extracellular matrix glycoprotein, implicated 
in cell adhesion, differentiation, migration, 
signaling and metastasis 
4.82 1.99 3.16 
4060 LUM Lumican Member of the small leucine-rich 
proteoglycan (SLRP) family that includes 
decorin, regulates collagen fibril organization, 
epithelial cell migration and tissue repair, 
binds to laminin 
8.53 3.75 5.45 
5118 PCOLCE Procollagen C-
endopeptidase 
enhancer (PCPE-1)
Secreted glycoprotein which drives enzymatic 
cleavage of type 1 procollagen and heightens 
C-protein activity, 
2.06 2.75 3.02 
63923 TNN Tenascin N Belongs to tenascin family, role in cell 
adhesion, migration, tumorigenesis 
3.17 2.18 2.23 
6678 SPARC  Secreted protein, 




Matrix-associated protein that elicits changes 
in cell shape, inhibits cell-cycle progression, 
regulates cell growth, influences ECM 
remodeling, interacts with collagen, 
thrombospondin, PDGF and cell membranes 
6.75 2.07 3.83 




Receptor for fibronectin and fibrinogen, 
functions in cell adhesion as well as cell 
surface mediated signaling 
2.83 1.92 2.44 
Proteolysis 
1513 CTSK Cathepsin K 
(pycnodysostosis) 
Lysosomal cysteine proteinase involved in 
extracellular matrix degradation, cell invasion, 
tissue remodeling 




















4318 MMP9 Matrix 
metallopeptidase 9 
(gelatinase B, 92 
kDa type IV 
collagenase) 
Local proteolysis of the extracellular matrix 
and in leukocyte migration, tumour-associated 
tumour remodeling, degrades collagen type IV 
and V 
1.68 2.10 2.89 
4320 MMP11 Matrix 
metallopeptidase 
11 (stromelysin 3) 
Breakdown of extracellular matrix, tissue 
remodeling, motility and metastasis, may play 
important role in epithelial malignancies 
3.67 6.35 9.95 
5238 PLAU Plasminogen 
activator, 
urokinase 
Serine protease involved in degradation of the 
extracellular matrix,  tumor cell migration and 
proliferation, interacts with PLAUR 
5.28 2.26 3.02 
5654 HTRA1 HtrA serine 
peptidase 1 
Protease that regulate availability of IGFs by 
cleaving IGF-binding proteins 
18.19 4.20 6.05 
Immunity & Inflammation 
3075 CFH Complement factor 
H (HF) 
Regulation of complement activation, IFN-γ 
induced 
 
4.18 1.77 2.12 
53342 IL17D Interleukin 17D Induces expression of IL-6, IL-8, and GM-
CSF from endothelial cells 
2.74 1.81 1.82 
Regulation of Transcription 
7291 TWIST1 Twist homolog 1 Transcription factor involved in cell lineage 
determination and differentiation, implicated 
in epithelial-mesenchymal transition, 
downregulates E-cadherin expression 




factor 4 (ITF2,  
E2-2) 
Transcription factor, interacts with β-catenin, 
downstream effector of Wnt signaling 
 






















Signal Transduction & Cell Communication 




Component of the CSF-1 signal transduction 
pathway, signaling via Grb2 
6.26 1.55 2.66 





Tyrosine kinase receptor for fibrillar collagen, 
mediates fibroblast migration and proliferation
4.55 1.92 2.65 




Cell surface tyrosine kinase receptor for 
members of the platelet-derived growth factor 
family which are mitogens for cells of 
mesenchymal origin 







Prostaglandin biosynthesis, regulates 
angiogenesis in endothelial cells, involved in 
cell-cell signaling and maintaining 
homeostasis, role in promoting cell 
proliferation in some normal and 
neoplastically transformed cell 
4.04 1.59 3.58 
6275 S100A4 S100 calcium 
binding protein A4 
(calvasculin, 
metastasin) 
Involved in cellular processes such as cell 
cycle progression and differentiation, altered 
implicated in tumor metastasis 
2.35 1.56 1.80 
8522 GAS7 Growth arrest 
specific 7 
Promote maturation and morphological 
differentiation of cerebellar neurons 
3.94 1.60 1.87 
652 BMP4 Bone morphogenic 
protein 4 
Belongs to the TGF-beta family involved in 
growth and differentiation, induces cartilage 
and bone formation, upregulation induces 
EMT 
1.52 3.29 1.79 
 
Results and Discussion 
Cell Adhesion Proteins 
The phenotypic transformation that occur as normal epithelial cells gain malignancy and 
invasiveness usually involve alterations in the expression of a wide number of genes 
involved in cell-to-cell and cell-to-extracellular matrix interactions, as well as in 
cytoskeletal reorganisation. Among the EMT-related genes detected in our microarray 
analysis, epithelial markers (ARPC2, STMN1, KRT14, LAMB3, PKP1, CALD1, CTNND1 
and CLDN8, 11, 19) were downregulated while mesenchymal markers (CDH2, CDH11, 
COL3A1, COL6A1, COL6A2, CSPG2, DCN, LAMB1, LUM, PCOLCE, TNN and SPARC) 
were upregulated.  
 
It is interesting that in the cases of ductal carcinomas we examined, the commonly cited 
epithelial marker, E-cadherin and mesenchymal marker, vimentin, were not 
downregulated or upregulated, respectively, as might be expected. On the contrary, 
lobular carcinomas do lack E-cadherin expression and show a diffuse invasion pattern37 
causing many to suggest lobular carcinoma as a more likely example of EMT in breast 
cancer. However, it appears that they do not frequently express EMT markers such as 
vimentin, SPARC or cadherin-1151. Additionally, investigators have been unable to find a 
correlation between Twist expression and the development of lobular carcinomas17. By 
contrast, we show in our study that SPARC (by microarray and IHC) and cadherin-11 (by 
microarray) is upregulated in ductal carcinomas. In addition, with regards to histology, 
tumour with basal-like phenotype have been found to be mostly invasive ductal 
carcinomas51. Coupled to recent findings that tumours with basal-like phenotype are more 
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prone to undergo EMT, it is highly likely that EMT occurs in ductal carcinomas, and not 
lobular carcinomas, even though E-cadherin expression is not necessarily downregulated. 
 
The mesenchymal markers, N-cadherin and a related gene, cadherin-11, were also found 
to be upregulated in our study. N-cadherin has been shown to facilitate cell motility, 
migration, invasion and metastasis in breast cancer cells73. Interestingly, research by 
Nieman et al. show that forced expression of N-cadherin in non-invasive, E-cadherin 
positive cells produces invasive cells, even though these cells continue to express high 
levels of E-cadherin. This N-cadherin-dependent motility may be mediated by the 
fibroblast growth factor (FGF) receptor signaling, promoting sustained activation of the 
MAPK-ERK pathway, leading to MMP-9 gene transcription (also upregulated in our 
study) and consequent cellular invasion. Cadherin-11 or OB-cadherin (osteoblast) is 
thought to mediate the interaction between tumour cells with fibroblasts or osteoclasts74, 
thus while de novo expression of N-cadherin might allow tumour cells to permeate the 
stroma, expression of cadherin-11 could confer homing ability to bone75. 
 
The identification of SPARC is also of particular interest. SPARC, together with THB1 
and THB2, belongs to a family of matricellular proteins functioning in mediating 
interactions between cells and their extracellular environment. SPARC recognition by 
αvβ5-integrin (ITGA5 upregulation was identified in our study) results in enhanced VEGF 
production in tumour cells thus favouring angiogenesis. A recent study by Lien et. al. on 
metaplastic carcinoma of the breast demonstrated intense expression of SPARC in the 
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sarcomatous tumour cells compared to the epithelial component, strengthening the case 
for the role for SPARC in EMT47. In line with the critical role of EMT in cancer invasion 
and metastasis, the expression of SPARC was found to be associated with poor overall 
survival in breast cancer patients; a finding concurred by a number of research 
groups47,76,77. A related protein, known as SPARC-like1, also known as hevin or mast9, is 
a member of the SPARC protein family that is also reported to be upregulated in IDC78. 
This gene was not included in our shortlist because although it was upregulated in all the 
cases we examined, upregulation in one case was 1.29 fold (while the other two was 
14.81 and 3.06), which is slightly less than our cut-off criteria of 1.5 fold change. 
SPARC-like1 serves as an antagonist to cell adhesion, playing a key role in the inhibition 
of attachment79.  
 
Claudins are tight junction associated proteins. Together with occludins, claudins interact 
with ZO-1, -2 and -3 to anchor the actin cytoskeleton. During EMT, tight junctions 
dissolve and their essential protein components are downregulated. Claudins have been 
shown to be downregulated in breast cancer and loss in expression is associated with 
increased cell dissociation, gain of cell motility, invasiveness and potential for 
metastasis80,81. Recent gene profiling work has come up with a new classification of 
claudin-low breast tumours that are enriched in EMT and stem-cell like features82.  
Downregulation of claudin is thought to occur during EMT, as it is also a downstream 
target of the E-cadherin suppressor, Snail1/216,80. In our study, we observed early 
downregulation of CLDN8, 11 and 19, suggesting that accumulation of events triggering 
EMT can occur as early as the normal to DCIS transition. 
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Lumican and decorin are members of the small leucine-rich proteoglycan family of 
proteins. This family of protein is able to modulate cellular behavior, including cell 
migration and proliferation during tumour growth. Increased levels of versican, a 
chondroitin sulphate proteglycan, have also been suggested to promote tumour migration 
and invasion due to their anti-adhesive effect on cells83.  Abnormal versican deposition 
has been observed in a number of tumour types, including breast cancer84.  These 
important markers of EMT, i.e. lumican, decorin and versican were identified to be 
upregulated in our study at the DCIS to IDC transition.   
 
Cytokeratin 14 is an intermediate filament and high molecular weight marker that 
associates with cytokeratin 5 to form the cytoskeleton of epithelial cells. Cytokeratin 14 
is thought to be downregulated in EMT46. Our study found consistent downregulation of 
cytokeratin 14 at the normal to DCIS transition, as soon as cells transform from normal to 









Results and Discussion 
Proteolytic Proteins and Inhibitors 
Our results show in general an upregulation of proteases (MMP 9, MMP 11, cathepsin K, 
cathepsin D, urokinase-type plasminogen activator and HtrA serine peptidase 1) and 
downregulation of protease inhibitors (maspin and tissue factor pathway inhibitor) in 
tumour cells, compared to normal epithelial cells. Matrix metalloproteases (MMPs) often 
play important role in epithelial malignancies as they function in local proteolysis of the 
extracellular matrix and collagen structrures surrounding tumour cells, thus facilitating 
cell migration and metastasis. Cathepsins are acid proteases often involved in the 
pathogenesis of breast cancer85. Maspin is a known tumour suppressor that prevents 
growth, invasion and metastasis properties of mammary tumours86. Downregulation of 
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Signal Transduction & Pathways 
In our study, we also identified a strong upregulation of PDGFRB. The PDGFRB gene 
encodes for a cell surface tyrosine kinase receptor for members of the platelet-derived 
growth factor (PDGF) family, which are strong mitogens for cells of mesenchymal 
origin. Jechlinger et al. recently implicated the involvement of PDGFRB in the metastatic 
potential of TGF-β-induced EMT in breast cancer cells46. Taken together, these data 
implies a novel application of PDGFRB inhibitor to therapeutically interfere with EMT in 
breast cancer. At present, a PDGFRB inhibitor already in the market, known as STI-571 
or imatinib, or more famously marketed as Gleevec® by Novartis, has been used in 
treating chronic myelogenous leukemia (CML) and a number of other malignancies. In 
laboratory settings however, imatinib is being used as an experimental agent to suppress 
PDGF by inhibiting PDGFRB. 
 
The fact that our shortlisted genes included several genes involved in Wnt signaling 
pathway is intriguing, as aberrant activation of Wnt signaling is common in many cancers 
and strongly associated with EMT87. Our data indicate downregulation of an antagonist 
of the Wnt signaling pathway, known as secreted frizzled related protein (SFRP3 or 
FRZB). FRZB is an important soluble modulator of Wnt signaling that is able to directly 
bind extracellular Wnt ligands, thus preventing ligand-receptor interactions and 
consequent signaling cascade88. A tumour suppressor role for FZRB have been 
suggested, and blocking Wnt signaling by FRZB leads to marked reduction in cell 
motility and invasiveness. In addition, expression of FRZB is also associated with 
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increased expression of epithelial markers (i.e. keratins 8 and 18) and decreased 
expression of mesenchymal markers (i.e. vimentin, N-cadherin, fibronectin, Slug and 
Twist)89,90. Our data also show an upregulation of TCF4, which is a transcription factor 
that is a downstream effector of Wnt signaling, as well as upregulation of a Wnt 
target/TCF transcribed gene, known as BMP4. BMP4 or bone morphogenic protein 4 
belongs to the TGF-β family involved in growth and differentiation, and upregulation of 
BMP4 induces EMT91-93. 
 
Other noteworthy transcription factors identified in our study include the upregulation of 
HOXB7 and TWIST1, which contain a homeobox and zinc finger DNA binding domains, 
respectively. HOXB7 and TWIST1 are transcription factors that have been shown, 
through in vitro studies, to modulate EMT in breast epithelial cells and are able to 
downregulate the expression of E-cadherin37,39. It is possible that although these effects 
are observable in vitro, the change in expression of HOXB7 and TWIST1 may not be 
sufficient to result in homogenous downregulation of E-cadherin in the tumour samples 
we studied, given that in vivo tumour microenvironments are much more complex and 
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4.4 Validation of Microarray Data 
To validate the quality of the microarray data, we examined selected genes whose 
expression is particularly well-coordinated in breast cancer cells. Following a method 
previously described47,94, we specifically examined the correlation coefficients for 
ERBB2 and GRB7 expression, with GRB7 being the neighbouring gene of ERRB2 and co-
amplified with it, as well as for distinctive co-expression pairs of cytokeratins, namely 
KRT8/KRT18 and KRT5/KRT14. We found highly positive correlation for ERBB2/GRB7 
(R2=0.84), KRT8/18 (R2=0.68) and KRT5/14 (R2=0.73) (Figure 16), which are good 
indications of the robustness of the microarray data.  
 
To further confirm our microarray findings, we performed QRT-PCR analysis using ABI 
TaqMan® Expression Assay for several differentially expressed genes. The QRT-PCR 
data correlated well with the patterns of expression revealed by microarray analysis. The 
candidate genes we selected for QRT-PCR and further IHC validation were KRT14 
(keratin 14), SERPINB5 (maspin), CDH2 (N-cadherin) and SPARC (SPARC) (Figure 
17). These genes were selected for further validation based on the availability of probe 






























































Figure 16. Correlation coefficients of co-expressed genes ERBB2/GRB7 (A), KRT8/KRT18 (B) and KRT5/KRT14 (C). The 
microarray fold change results of each pair of genes were plotted at x- or y-axis, respectively. The co-expression of the genes were 












Results and Discussion 
Figure 17. Validation of microarray 
data by QRT-PCR. KRT14 and 
SERPINB5 were downregulated at the 
normal to DCIS transition (A), while 
CDH2 and SPARC were upregulated at 
the DCIS to IDC transition (B). 
Average fold changes and associated 
standard errors of the mean were 
plotted. Data are averages of duplicate 
measurements. Paired Student’s t-test 
was used to analyse the difference in 
transcript levels, where DCIS was 
referenced to normal (A) or IDC was 
referenced to DCIS (B). p-values for all 
genes were found to be <0.05. The 
QRT-PCR results were consistent with 
the direction of expression as revealed 
by microarray analysis. 
























































































































Results and Discussion 
4.5 Further Validation by IHC 
4.5.1 N-cadherin 
Assessment of Staining 
N-cadherin expression was negative in normal breast epithelium. However, of the 30 
cases examined, distinct membranous staining was found in clusters of tumour cells in 2 
cases of DCIS (7%) and 8 cases of IDCs (27%) (Table 7; Figures 18, 19 and 20). 
Statistical analysis by Chi-square revealed that N-cadherin is significantly upregulated in 
IDC compared to DCIS and normal breast epithelium (p<0.05).  This increase in N-
cadherin expression was observed primarily at the DCIS to IDC transition, and not during 
normal to DCIS transition, suggesting that upregulation of N-cadherin occurs late during 
tumour progression. No statistically significant correlation between N-cadherin 
expression in IDC and various clinicopathological variables was identified (Table 8). 
 
Further examination revealed that in some cases, there was co-expression of E-cadherin 
and N-cadherin, while in some areas there were inverse expressions of E-cadherin and N-
cadherin (Figure 21). Full data for E-cadherin immunostaining (30 cases) is not shown, 
but specific relevant examples are provided here in the interest of discussion. In general, 
E-cadherin immunostaining is positive and heterogenous, with differing levels of 
intensity throughout the tumour, with some tumours having small clusters of negative 
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Table 7. Observed frequency of N-cadherin staining intensities in 30 cases of breast 
carcinoma.  
Intensity/ Negative (0) Positive (1 – 3) Total No. 
Proportion No. (%) No. (%) 
Normal 30 (100) 0 (0) 30 
DCIS 28 (93) 2 (7) 30 
IDC 22 (73) 8 (27) 30 
Normal v DCIS v IDC; χ2 = 11.70, df = 2, p < 0.05 
Normal v DCIS; χ2 = 2.07, df = 1, p > 0.05 












Results and Discussion 
Table 8. Correlation between N-cadherin positivity and clinicopathological variables 
in IDC of the breast. 
 
Total 
N-cad expression in IDC 
 p-value Negative 
(0) 
Positive 
(1 – 3) 
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Figure 18. N-cadherin immunostaining in 
normal breast epithelia. N-cadherin is absent 
in normal breast epithelia of the duct (arrow) 
and lobules (arrowheads). 
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 DCIS DCIS 















Figure 19. N-cadherin immunostaining in DCIS of the breast. N-cadherin is 
negative (arrows) in the majority of DCIS cases we studied but was nevertheless, 
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 IDC IDC 










   
D A 
Figure 20. N-cadherin immunostaining in 
IDC of the breast. In some breast tumours, 
N-cadherin was strongly expressed in IDCs. 
Intense, complete membranous staining was 
observed (arrows). Interestingly, clusters of 
cells negative for N-cadherin were also 
detected, located just adjacent to N-cadherin 
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Discussion 
Cadherins (Calcium-dependant adhesion molecules) are a superfamily of adhesion 
molecules that play important roles in the regulation of cell-cell interactions during 
development and tissue morphogenesis. Cadherins are transmembrane glycoproteins that 
promote calcium-dependent cell-cell adhesive interactions. Their important interacting 
partners include a family of catenins that interact with the cytoplasmic domain of 
cadherins to instigate various signaling pathways. E-cadherin is the prototypical member 
of this superfamily that is expressed in epithelia. Other well-characterised cadherins 
include N-cadherin, which is expressed in neural tissue, muscle and fibroblasts; R-
cadherin, in the forebrain and bone; P-cadherin in the basal-layer of stratified epithelia 
and VE-cadherin in endothelial cells95. 
 
In recent years, cadherins have been increasingly considered as one of the hallmarks of 
EMT, as transdifferentiation of epithelial carcinoma cells into a more mesenchymal 
phenotype involves the breakdown of adherens junctions and changes in associated 
molecules such as cadherins. A process coined as “cadherin switching” have been 
associated with EMT, whereby a concomitant downregulation of E-cadherin and 
upregulation of N-cadherin is said to take place in neoplastic cells acquiring invasive 
properties75,96,97. It can be hypothesised that the function of cadherin switching in EMT is 
to allow epithelial cells to separate from one another and to acquire a more motile 
phenotype, as occurs during gastrulation for example. These cells lose their affinity for 
epithelial neighbours and gain affinity for mesenchymal cells, such as fibroblasts or 
  88 
 
Results and Discussion 
vascular endothelial cells. Attributes like these promote motility, invasion, extravasation 
and ultimately distant metastasis.  
 
The signal from the microenvironment responsible for triggering cadherin switching may 
well be the same signal that triggers EMT in breast cancer, TGF-β. TGF-β appears to 
have a paradoxical effect on tumours, in that, while it suppresses growth of normal 
epithelial cells, it also has tumour promoting properties18,21. During TGF-β-mediated 
EMT in cell lines, E-cadherin expression is decreased while N-cadherin is increased46.  
 
With regards to mechanism of action, data from breast cancer cell lines studies suggest 
that N-cadherin dependent motility may be mediated by the fibroblast growth factor 
(FGF) receptor signaling73,98. N-cadherin is able to prevent ligand-induced internalisation 
of the FGF receptor (FGFR-1), resulting in increased FGFR-1 stability. Thus, in the 
presence of N-cadherin, FGF-2 binds to the FGF receptor and causes a sustained 
activation of the MAPK-ERK pathway, leading to gene transcription of MMP-9, an 
extracellular matrix protease. The result is increased scattering and motility in breast 
cancer cells co-expressing E- and N-cadherin. 
 
In our study, we found that N-cadherin was upregulated in 27% (8/30 cases) of IDCs 
even though N-cadherin was entirely absent in normal breast epithelia. This figure 
appears to be lesser than a similar study by Nagi et al. where N-cadherin was expressed 
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in 52% (37/71 cases) of IDCs45. This slight disparity in percentage of N-cadherin positive 
cases may be due to the fact that our sample size is smaller or that the minimum threshold 
for a positive call, which was not defined specifically by the authors, may be different 
from ours. We used a threshold of more than 10% of cells for a positive call, but there 
have been reports using a positive threshold as low as 1%51,99. Regardless, we still found 
a statistically significant trend of N-cadherin upregulation in IDCs much like Nagi et al. 
Upregulation of N-cadherin have also been reported in colorectal cancer (44%; 35/80 
cases)100, prostate cancer (37%; 35/94 cases)101 and lung cancer (31%; 46/150 cases)102. 
Moreover, the study by Nagi et al. showed that N-cadherin was also significantly 
upregulated in invasive micropapillary breast carcinomas (76%, 32/42 cases)45, which is 
a more aggressive breast tumour subtype highly prone to distant metastasis.  
 
The upregulation of mesenchymal marker, N-cadherin and simultaneous downregulation 
of epithelial marker, E-cadherin is often quoted as a hallmark of EMT. However, it is 
unclear whether E-cadherin loss is a compulsory or critical component of EMT and 
invasion for all cancers. While convincing evidence for loss of E-cadherin at the invasive 
front have been shown in colorectal cancer57, E-cadherin is certainly not lost, at least 
never entirely or permanently, in ductal carcinomas of the breast, and thus, it is probable 
that E-cadherin dysfunction is not crucial in ductal carcinomas.  
 
In fact, interesting work by Nieman et al. show that forced expression of N-cadherin in 
non-invasive, E-cadherin positive cells produced an invasive cell, even though these cells 
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continue to express high levels of E-cadherin103. Several other studies have also shown 
that N-cadherin expression in cells induces cell migration, invasion and metastasis, 
despite positive E-cadherin expression. Conversely, induced E-cadherin expression in N-
cadherin expressing breast tumour cells did not suppress cellular invasiveness73,98,103.        
 
Indeed, we also found that in the IDCs that did express N-cadherin, there was often co-
expression of E-cadherin and N-cadherin. In a few cases however, there appeared to be 
varying degrees of E-cadherin downregulation in clusters of cells where N-cadherin is 
expressed, resembling a process known as cadherin switching (Figure 21). It appears that 
our observations of E- and N-cadherin co-expression are consistent with similar reports in 
breast cancer and colorectal cancer45,100. The presence of an E- and N-cadherin co-
expression, suggests a possible alternate mechanism for regulating cadherin function 
rather than via the transcriptional repression by Twist or Snail and β-catenin 
nuclearisation following Wnt signaling activation, as proposed for colorectal cancer57. In 
support of this view, experimental results in our laboratory showed that β-catenin staining 
(data not shown) correlated very well with E-cadherin, that is, membranous and strong, 
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Figure 21. Comparison between E-cadherin and N-cadherin immunoreactivity. In general, breast ductal carcinomas as 
strongly positive for E-cadherin and negative for N-cadherin (A, B). However, in a proportion of carcinomas, N-cadherin is 
upregulated in the invasive cells, while E-cadherin expression is maintained, albeit in a lesser intensity (C, D). This co-expression 
of N- and E-cadherin in epithelial cells is intriguing, possibly suggesting an onset of EMT. Although less frequently, it was also 
observed that in a few cases, E-cadherin expression is significantly downregulated or lost in clusters of invasive ductal carcinoma 
cells. In these clusters, N-cadherin is concomitantly upregulated, resembling a process known as “cadherin switching” (E, F).      
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These data suggest that in ductal breast carcinomas, downregulation of E-cadherin may 
not be as crucial as the upregulation of N-cadherin or that N-cadherin is more dominant 
over E-cadherin for progression from in situ to invasive carcinoma during cancer 
progression. It has been suggested that co-expressions of these cadherins could indicate 
an evolution of the tumour from an E-cadherin, to E-cadherin-N-cadherin, to an N-
cadherin expressing tumour, reflecting tumour heterogeneity relating to advancing stages 
of malignant progression45. Since EMT is a dynamic, transient and reversible process, it 
is plausible that tumour cells go back and forth in expressing these cadherins, as they 
respond to signals from the microenvironment at any given time. Hence, cadherin 













Results and Discussion 
4.5.2 SPARC 
Assessment of Staining 
SPARC stains in the cytoplasmic component of cells. In our study, SPARC appears to be 
absent or expressed in low levels in the majority of normal breast epithelia (83%; 25/30 
cases). A large proportion of DCIS showed positive or strong expression of SPARC 
(40%, 12/30 cases), which was statistically significant. The upregulation of SPARC 
becomes significantly more prominent in IDCs where strong, positive expression of 
SPARC was observed in 73% or 22 out of 30 cases studied. Chi-square tests indicate that 
SPARC increases in a stepwise manner following tumour progression, where the increase 
at the normal to DCIS transition (p<0.05) as well as at the DCIS to IDC transition 
(p<0.05) is statistically significant (Table 9, Figures 22, 23 and 24) 
 
Incidentally, we also observed that the stromal cells surrounding the IDCs also show an 
increase in SPARC expression, ranging from moderate to extensive. In contrast, the 
stroma surrounding normal glands or DCIS showed minimal or no positivity for SPARC. 
(Table 10, Figure 24). More specifically, moderate to extensive SPARC 
immunopositivity was observed in the surrounding stromal cells of 70% of IDC cases 
(21/30), 17% of DCIS cases (5/30) and none of the normal breast epithelia. No 
statistically significant correlation between SPARC expression in IDC and various 
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Table 9. Observed frequency of SPARC staining intensities in 30 cases of breast 
carcinoma. 
Intensity/ Negative/Weak (0-1) Positive/Strong (2-3) Total No. 
Proportion No. (%) No. (%) 
Normal 25 (83) 5 (17) 30 
DCIS 18 (60) 12 (40) 30 
IDC 8 (27) 22 (73) 30 
Normal v DCIS v IDC; χ2 = 19.82, df = 2, p < 0.05 
Normal v DCIS; χ2 = 4.02, df = 1, p < 0.05 
DCIS v IDC; χ2 = 6.79, df = 1, p < 0.05 
 
Table 10. Observed frequency of SPARC staining intensities in the surrounding 
stromal cells in 30 cases of breast carcinoma.  
Extent/ None/Minimal Moderate/Extensive Total No. 
Proportion No. (%) No. (%) 
Normal 30 (100) 0 (0) 30 
DCIS 25 (83) 5 (17) 30 
IDC 9 (30) 21 (70) 30 
Normal v DCIS v IDC; χ2 = 39.05, df = 2, p < 0.05 
Normal v DCIS; χ2 = 5.46, df = 1, p < 0.05 




Results and Discussion 
Table 11. Correlation between SPARC positivity and clinicopathological variables 
in invasive ductal carcinoma of the breast. 
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 Figure 22. SPARC immunostaining in normal breast and IDC. SPARC is absent 
in normal breast epithelia (B, C) but strongly expressed in invasive cells (B, D). 
Interestingly, these SPARC-overexpressing invasive cells appear to be associating 
with inflammatory cells (i) and lymphatic and vascular vessels (lv) nearby, 
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Figure 23. SPARC immunostaining in DCIS 
of the breast. SPARC is overexpressed in a 
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 IDC IDC 























Figure 24. SPARC immunostaining in IDC of the breast. SPARC is significantly 
overexpressed in invasive cancer cells, primarily localising to the cytoplasm of these 
cells (B, C). A blood vessel (lv) can be seen nearby the SPARC-overexpressing cells. 
In some tumours, although the neoplastic cells may express low to moderate levels of 
SPARC, the stromal cells surrounding IDCs show an increase in SPARC expression, 
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Discussion 
SPARC (Secreted Protein Acidic and Rich in Cystein), also known as osteonectin and 
BM40, belongs to the matricellular family of secreted proteins, which also includes 
thrombospondins 1 and 2, osteopontin and tenascins C and X104,105. SPARC is a highly 
conserved secreted glycoprotein that has the ability to bind to a myriad of extracellular 
matrix proteins, functioning to mediate interactions between cells and their extracellular 
environments. It is reported to be expressed as early as during embryogenesis and 
development106,107. In the adult, SPARC modulates tissue remodeling and repair, growth 
factor efficacy, angiogenesis as well as regulate morphogenesis and cellular 
differentiation77,108. At present, there is a host of publications describing the association 
of SPARC with many types of cancers and is widely regarded as an oncogenic protein. 
Upregulation of SPARC is associated with metastatic potential of melanomas and 
gliomas as well as invasive phenotype of breast, prostate and colorectal carcinomas108.  
 
Indeed, our results also showed that, while normal breast epithelia express little or no 
SPARC, levels of the protein were significantly elevated in DCIS (40%; 12/20 cases) and 
even more prominently in IDC (73%, 22/30 cases). Our protein expression data appears 
highly concordant with data from our microarray analysis, which showed a significant 
upregulation of SPARC mRNA expression during the progression from in situ to invasive 
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Our data seems to be consistent with the findings of Porter et al.109, who were first to 
report the distribution of SPARC in normal and neoplastic human tissue, whereby 
SPARC was positive in 88% or 30/34 cases of mammary carcinomas they examined. 
Glandular breast epithelial cells were reported to express low levels of SPARC. 
Additionally, similar to our observations, they also made mention of the fact that high 
levels of SPARC was also seen in tumour-associated stromal fibrocytes (Figure 24). This 
observation was also reported in various other publications77,110. Although SPARC binds 
to components of the extracellular matrix, it does not appear to be incorporated into the 
matrix per se. In agreement with Porter et al.’s findings, we did not find significant 
staining of the basement membrane or extracellular regions.     
 
Little is known about the precise mechanisms of SPARC activity. However, SPARC is 
thought to have the capacity to induce metalloproteinases such as collagenase, 
stromelysin and 92 kD gelatinase, that degrade both interstitial and basement membrane 
matrices111. Our microarray data reflected a downregulation in the mRNA expression of 
stromelsyin-3 (MMP-11) and 92 kDa gelatinase (MMP-9) which supports this view. 
Another study suggests that SPARC recognition by αvβ5-integrin (ITGA5 upregulation 
was identified in our microarray study) results in enhanced VEGF production in tumour 
cells thus favouring angiogenesis. In an autocrine manner, cells expressing VEGF or 
VEGFR-2 will further activate integrins αvβ3 and αvβ5 on their surface and use these 
integrins to migrate112, likely towards the bone, where SPARC is constitutively and 
highly expressed in osteocytes. Apart from VEGF, SPARC also appears to regulate the 
activity of other growth factors such as PDGF and FGF-2113.  
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Data from proteomic studies done by Sosa et al. on melanoma cells showed that 
downregulation of SPARC expression by siRNA resulted in decreased levels of N-
cadherin. Transient re-expression of SPARC in these RNA-silenced cells also reverted 
expression of N-cadherin to levels similar to the cells before silencing. Their results 
constitute the first evidence that SPARC and N-cadherin may converge in a unique 
molecular network114. Other research reports that SPARC is able to induce cell cycle 
arrest, through inhibition of progression of cells from G1 to S-phase113. The inhibitory 
effect of SPARC on the cell cycle is likely to be beneficial for cell migration, an activity 
that requires the cessation of cell cycle and proliferation.  
 
In a more recent study, Robert et al. provided novel evidence for the mechanism of 
SPARC in the transformation of melanocytes. They showed that expression of SPARC 
results in transcriptional downregulation of E-cadherin, which correlates with the 
induction of Snail, a known repressor of E-cadherin. In addition, cells overexpressing 
SPARC adopted fibroblast-like morphology, concomitant with increased expression of 
mesenchymal markers like vimentin, fibronectin and Lef-1115. In our study however, we 
did not see an obvious downregulation of E-cadherin nor the upregulation of Snail. 
Nevertheless, we feel that SPARC may still play an important role in EMT in ductal 
carcinomas via the other possible mechanisms and interactions described earlier. For 
example, our results do show the upregulation of MMP-11, MMP-9 and N-cadherin, 




Results and Discussion 
In addition to the recognised role of SPARC as an anti-adhesive protein that contributes 
to the release of tumour cells from the extracellular matrix, thus promoting migration and 
metastasis, SPARC has also been strongly associated with EMT. For example, expression 
profiling of TGF-β-induced EMT in Ras-transformed mammary EpH4 cells shows 
upregulation of SPARC46. Genetic profiling of Snail, Slug and E47-induced EMT in 
MDCK epithelial cells also reveals an upregulation of SPARC70. In IHC studies 
involving metaplastic carcinoma of the breast by Lien et al., SPARC has been shown to 
be strongly upregulated in the sarcomatous component of the tumour, while the 
carcinomatous component remains immunonegative (n=2)47. A similar IHC study carried 
out by Sarrio et al. also reported the same observation. Of the 12 metaplastic carcinomas 
they examined, 5 carcinomatous (epithelial) components and 10 sarcomatous 
(mesenchymal) components were positive for SPARC51.  Thus, in a myriad of recent 
publications on the topic of EMT, SPARC is now often cited as a mesenchymal marker 
upregulated in EMT. The observation that 73% of IDCs in our study express SPARC to 
varying degrees, leads us to believe that EMT does indeed occur in ductal carcinomas of 








Results and Discussion 
4.5.3 Keratin 14 
Assessment of Staining 
In normal breast, keratin 14 is expressed by the myoepithelial cells in the terminal duct 
lobular units (TLDU). In all cases, immunopositivity is strong, complete and 
membranous. In contrast, the luminal epithelial cells in TDLUs do not express keratin 14. 
However, keratin 14 expression is dramatically lost in 53% or 16 of 30 cases of DCIS 
and in 83% or 25 of 30 cases of IDC (Table 12; Figures 25, 26 and 27). Chi-square tests 
indicate the loss of keratin 14 in DCIS as well as IDC is statistically significant when 
compared against normal breast epithelia, as well as between each other. Thus, our results 
indicate that keratin 14 expression is downregulated in a stepwise manner in tumour 
progression, that is, at the normal to DCIS transition and as well as at the DCIS to IDC 
transition. No statistically significant correlation between loss of keratin 14 expression in 










Results and Discussion 
Table 12. Observed frequency of keratin 14 staining intensities in 30 cases of breast 
carcinoma. 
Intensity/ Negative (0) Positive (1 – 3) Total No. 
Proportion No. (%) No. (%) 
Normal 0 (0) 30 (100) 30 
DCIS 16 (53) 14 (47) 30 
IDC 25 (83) 5 (17) 30 
Normal v DCIS v IDC; χ2 = 43.09, df = 2, p < 0.05 
Normal v DCIS; χ2 = 21.82, df = 1, p < 0.05 













Results and Discussion 
Table 13. Correlation between keratin 14 positivity and clinicopathological variables 
in invasive ductal carcinoma of the breast. 
 
Total 
Keratin 14 expression in IDC 
p-value  Negative 
(0) 
Positive 
(1 – 3) 
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Figure 25. Keratin 14 immunostaining in normal breast and skin. Keratin 14 is 
strongly expressed in the basal epithelial layer of normal ducts and lobules (B, C) as 
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 DCIS DCIS 













D Figure 26. Keratin 14 
immunostaining in DCIS of the 
breast. In some DCIS, the 
expression of keratin 14 at the 
basal epithelial layer is preserved 
(arrows) (B, C). However, in a 
majority of DCIS, keratin 14 
expression is lost (arrowheads) 
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Figure 27. Keratin 14 immunostaining in 
IDC of the breast. Keratin 14 is completely 
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Figure 28. Aberrant keratin 14 overexpression in IDC. In a number of IDC cases, 
keratin 14 is aberrantly overexpressed. Keratin 14 immunopositivity is a marker for 
the basal-like phenotype of breast cancer that is strongly associated with poor 
prognosis. In some tumours, there is a mixed population of keratin 14 positive 
(arrows) and negative cells (arrowheads), located side by side, demonstrating diverse 
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Discussion 
The cytoskeleton in all mammalian cells is comprised of 3 types of filaments: actin 
microfilaments (4-6 nm), intermediate filaments (10 nm) and the microtubules (25 nm). 
Expression of the intermediate filament proteins, particularly cytokeratins, reflects the 
epithelial cell type, state of tissue growth, differentiation and functional status of the 
cell116. In normal breast, the luminal epithelial and the basal myoepithelial cells exhibit 
distinctly different keratin phenotypes. Luminal epithelial cells express simple epithelial 
keratins, CK 7/8, 9, 18 and 19, while the basal myoepithelial cells express smooth muscle 
actin (SMA) and CK 5/6, 14 and 17. 
 
Using microarray and QRT-PCR, we found the mRNA expression of KRT14 to be 
downregulated at the normal to DCIS transition, which persisted in IDC. We expected the 
immunohistochemical results to validate our gene expression findings and show a similar 
downregulation trend. Indeed we found this to be true, in that, keratin 14 protein 
expression was indeed lost in DCIS (53%, 16/30 cases) and IDC (83%, 25/30 cases).  
 
Loss of keratins represents one of the molecular hallmarks of EMT. Typically, keratin 
filaments insert at desmosomes and hemidesmosomes117. Thus, loss of expression results 
in the impairment of cell-to-cell adhesion, basement membrane attachment and 
association to underlying connective tissue. Since keratins are important structural 
stabilisers of epithelial cells, dysregulation of cytoskeletal organisation promotes tumour 
cell motility and favours cellular migration. Beyond their mechanical roles, keratins are 
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also thought to play a role in membrane traffic and signaling by serving as scaffold 
proteins, thus influencing epithelial polarity118. The absence of this scaffolding function 
following loss of keratin expression may result in the derangement of apico-basal 
polarity, which is another hallmark of EMT. Weak keratin expression have been detected 
in patients who develop recurrence or metastastic disease, in addition to being associated 
with reduced overall survival119. 
 
While a majority of tumours did show a downregulation of keratin 14 by IHC, to our 
surprise, there were a handful of IDC cases (n=5) where strong keratin 14 
immunopositivity was observed (Figure 28).  For some years, it has been recognized that 
2-18% of IDCs show focal or diffuse expression of cytokeratins that are normally found 
in the outer, contractile basal myoepithelial layer of normal breast ducts and acini120,121. 
Different investigators have used their own preferred name, such as basaloid121, basal-
like122 or ductal cancer with myoepithelial phenotype123 to describe them. The poor 
prognostic impact of basal cytokeratin expression in breast cancer was first suggested by 
Dairkee et al. in 1987124, but this class of tumours did not receive much attention until 
after its identification in gene expression profiling studies as a molecularly distinct 
subtype of breast cancer, more than 10 years later.  
 
Gene expression profiling studies pioneered by Perou et al.48 established for the first time 
that breast cancer could be classified into molecularly distinct groups based on global 
gene expression profiles. According to the molecular classification by Perou et al., breast 
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carcinomas can be divided into at least four distinct subtypes: (i) normal-like phenotype, 
(ii) luminal/ER+ phenotype, (iii) ER–/ERBB2 overexpressing phenotype and (iv) basal-
like phenotype48,49. Basal-like phenotype comprises tumours expressing markers 
characteristic of the myoepithelium of the normal mammary gland. These include 
expression of p63, SMA, calponin, S100 protein, CK5/6 and of particular interest in our 
study, basal cytokeratin CK14. 
 
Hence, despite the luminal origin of breast tumours, Perou et al.’s findings indicate that a 
subset of invasive ductal carcinomas also express markers for myoepithelial cells. It is 
difficult to speculate which cells these tumours may be derived from, but currently, there 
is little evidence to suggest a myoepithelial origin for basal-like breast cancers. Instead, it 
is believed that committed epithelial cells still retain their intrinsic ability to switch on its 
myoepithelial differentiation programme125. In addition, recent studies by Sarrio et al. 
found that EMT-like changes, such as the upregulation of mesenchymal markers (e.g. N-
cadherin and cadherin-11) and overexpression of proteins involved in extracellular 
remodeling and invasion (e.g. SPARC), together with the reduction of epithelial markers 
(E-cadherin and cytokeratins) preferentially occurred in tumours with the basal-like 
phenotype51. The proclivity of basal-like cells to a mesenchymal transition may be related 





Results and Discussion 
These data point to the plasticity of breast carcinoma cells and their capacity to undergo 
EMT in differing situations. While downregulation of cytokeratins in general and loss of 
cellular polarity have been long considered typical hallmarks of EMT, there is now new 
evidence to suggest that breast tumours demonstrating aberrant overexpression of basal 
cytokeratins in particular (CK5 and CK14), belong to a distinct subtype of breast cancer 
that is especially prone to undergoing EMT-like changes. Clearly, much work still needs 















Results and Discussion 
4.5.4 Maspin  
Assessment of Staining 
In normal breast tissue, the myoepithelia were vividly stained for maspin in all cases, 
both in the nucleus and in the cytoplasm. Positive staining was also observed in the 
luminal epithelia, albeit to a slighly lesser intensity. By contrast, while staining of the 
perileisonal myoepithelium of DCIS were usually preserved, the neoplastic epithelial 
cells exhibited lower immunoreactive scores and lower percentage of positive cells and 
these indices were further decreased in invasive carcinomas (Figures 29, 30 and 31). 
Downregulation of maspin expression was observed in 33% or 10 of 30 DCIS cases and 
53% or 16 of 30 IDC cases (Table 14). Chi-square tests revealed that the downregulation 
at the normal to DCIS transition was statistically significant, but not at the DCIS to IDC 
transition. This implies that maspin is lost early at the normal to DCIS transition and this 
decrease is sustained in IDC. No statistically significant correlation between loss of 









Results and Discussion 
Table 14. Observed frequency of maspin staining intensities in 30 cases of breast 
carcinoma. 
Intensity/ Negative (0) Positive (1 – 3) Total No. 
Proportion No. (%) No. (%) 
Normal 0 (00) 30 (100) 30 
DCIS 10 (33) 20 (67) 30 
IDC 16 (53) 14 (47) 30 
Normal v DCIS v IDC; χ2 = 21.20, df = 2, p < 0.05 
Normal v DCIS; χ2 = 12.00, df = 1, p < 0.05 












Results and Discussion 
Table 15. Correlation between maspin positivity and clinicopathological variables in 
invasive ductal carcinoma of the breast. 
 
Total 
Maspin expression in IDC 
p-value  Negative 
(0) 
Positive 
(1 – 3) 
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Figure 29. Maspin immunostaining in 
normal breast epithelia. Maspin is strongly 
expressed in the myoepithelial layer of normal 
ducts (arrows) and lobules (arrowheads) as 
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 DCIS DCIS DCIS 
H & E 
100 X 
Figure 30. Maspin 
immunostaining in 
DCIS of the breast. 
DCIS staining may 
show a well-preserved, 
strongly immuno-
positive myoepithelial 
cell layer and a weak to 
moderately positive 
expression in neoplastic 
epithelial cells (B, C). 
However in most 
tumours, only the 
myoepithelial cells stain 
positive (E, F) while in 
other tumours, maspin 
is completely lost, both 
in the myoepithelial 
layer as well as in the 
neoplastic cells (H, I). 
The few normal ducts 
(red arrows) that are 
present act as internal 
positive control to 
confirm validity of 
staining technique. 
   
100 X 
   
400 X 
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Figure 31. Maspin immunostaining in IDC of the breast. Maspin is significantly 
downregulated in invasive cells. Normal ducts act as internal positive controls (red 
arrows) (B, C). In some tumours, maspin appears overexpressed (E, F), and localises 
not only to the cytoplasm of cells, but also to the nucleus (arrowheads).  
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Discussion 
Maspin, or Mammary Serine Protease Inhibitor, was first reported in 1994 as a serpin 
with tumour suppressive properties. Zou et al. found the 42-kDa protein to be expressed 
in normal mammary tissue but is reduced or absent, particularly in advanced breast 
carcinomas126. Subsequent research further portrays maspin to be a multifaceted protein 
with ability to inhibit cell invasion, reduce cell motility, increase cell adhesion, promote 
apoptosis, inhibit angiogenesis and is critically involved in mammary gland 
development86,127.   
 
Since the first report by Zou et al., many new reports emerged to further validate their 
findings. Hojo et al. reported that maspin-positive breast cancer showed a low 
pathological grade of malignancy, such as a lower infiltration of neoplastic cells into the 
surrounding tissue and a downregulation of c-erbB2 expression, as well as a decrease in 
tumour vessels128. Using RT-PCR, Maass et al. found that the maspin transcript was lost 
in 16 of 45 (36%) breast cancer specimens. This downregulation of maspin in breast 
cancer was associated with higher risk of distant metastasis and short disease-free 
survival. 6 of 8 patients who developed distant metastasis within 3 years had maspin-
negative tumours129. Their group went on further to show a stepwise decrease in maspin 
expression in the progression of ductal carcinomas of the breast, by performing IHC on a 
large series of normal glands (n=7), DCIS (n=12), IDC (n=128) and their lymph node 
metastases (n=65)130. Similar findings have been reported in various cancer types, 
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including recent IHC studies on pancreatic ductal carcinoma (n=223)131 and malignant 
melanoma (n=88)132 and many others. 
 
Nevertheless, there have been reports that strongly contrast the findings mentioned 
above. For example, Lee et al.’s findings suggest that maspin expression is not 
downregulated with the progression of breast cancer, and may in fact, be associated with 
poor prognosis. Maspin-positive IDCs correlated with higher histologic grade, larger 
tumour size and shorter survival133. These findings were supported by Umekita et al. who 
argue that maspin expression not only predicts poor prognosis and is associated with 
shorter relapse-free survival, but is in fact, upregulated during the progression of 
mammary ductal carcinoma134,135. Lee et al. and Umekita et al.’s criticism of Maass et 
al.’s study was that the number of DCIS was small (n=12). Also, they questioned the 
results from the RT-PCR study by Maass et al. given that mammary myoepithelial cells 
surrounding the normal ducts and non-invasive ductal components express maspin, which 
may potentially confound data generated from total RNA extracted from crude cancer 
specimens.  
 
Our study has in fact addressed the issue of potential contaminating cells by employing 
the use of LCM technique to procure a purer neoplastic population. Admittedly, to isolate 
normal ductal cells without any contaminating myoepithelial cell would be difficult, 
given the size of a normal duct or lobule and the limitation to how small the laser beam 
can be adjusted. However, in DCIS and IDC, procuring a purer population of neoplastic 
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ductal cells and avoiding majority of the myoepithelia is possible and was performed. By 
both microarray and quantitative real-time PCR, our results showed that maspin was 
downregulated in DCIS and IDC, compared to normal ducts the cases we examined. Our 
RNA expression results were further validated at the protein level by IHC on a larger 
sample size. Again, we found a decrease in maspin expression in DCIS (33%) and IDC 
(53%) compared to normal glands, which was statistically significant. Thus, it appears 
that both our RNA and protein data agrees with the findings of Maaas et al.   
 
The high maspin expression in the myoepithelial cells is in keeping with the notion that 
the myoepithelium is a ‘natural tumour suppressor’136 because they defend against 
stromal invasion by the production of high levels of matrix proteins and protease 
inhibitors, maspin being one of them. In addition, the myoepithelium is capable of 
inducing apoptosis in breast carcinoma cells and inhibit angiogenesis, which 
unsuprisingly are also the attributes of maspin. The loss of maspin as cells become 
neoplastic could play a role in the acquisition of an invasive phenotype in these cells. The 
absence of the protease inhibitor would allow increased extracellular matrix degradation, 
tumour cell motility and invasion.  
 
The mechanisms through which maspin expression is lost in advanced tumours are not 
fully understood. Abberant promoter hypermethylation have been shown to account for 
the silencing of maspin gene expression137. In addition, maspin is located at chromosome 
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18q21.3, a region that often undergoes loss of heterozygosity in some form of human 
cancers138.     
 
Additionally, a recent paper published in 2009 reported a link between maspin expression 
and EMT. Cai et al.139 showed that maspin re-introduction into a maspin-null esophageal 
cancerous cell line, EC109 prevented EGF-induced EMT in these cells. With exposure to 
EGF, the morphology of the parental EC109 switched from an epitheloid, cobblestone-
like appearance to spindle-like shape and became scattered, demonstrating EMT. In 
addition, expression of pan-cytokeratin increased and vimentin decreased, which are 
lineage markers for epithelial and mesenchymal cells respectively. In contrast, maspin-
transfected EC109 cells remained tightly clustered and did not show altered levels of pan-
cytokeratin or maspin despite EGF exposure. Furthermore, while EGF significantly 
promoted the migration and invasion potential of EC109 cells, it had no such effect on 
maspin-transfected cells. These results show that maspin was able to inhibit EGF-induced 
EMT in EC109 cells, indicating an important metastasis-suppresive role.  
 
Curiously, there were a handful of cases (n=6) where maspin expression in IDC was 
exceptionally high (3+ score for intensity) in the cytoplasm and nucleus (Figure 30). The 
overexpression of maspin in the cytoplasm and nucleus of a number of IDC does seem to 
be contradictory to the known functions of maspin. However, as the precise mechanisms 
of aberrant expression of maspin in carcinoma cells remains unclear, some possibilities 
may be suggested. Firstly, mutation of the maspin gene could cause loss of normal 
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function and secondly, a high intracellular concentration of maspin could result in auto-
inhibition of its activity by non-covalent polymerisation140. 
 
Indeed, the loss of maspin as well as the occasional aberrant overexpression of maspin in 
invasive breast cancer cells proves to be quite a fascinating topic which warrants 
attention and further studies. Finally, although there have been paraxodical findings in the 
expression of maspin in various cancer types, the bulk of accumulated evidence from in 
vitro and in vivo studies, as well as our own study, point to the multifaceted role of 













5. GENERAL DISCUSSION 
5.1 Significance of Technique Employed 
In recent years, one of the most active areas in human breast cancer research has been the 
molecular profiling of breast tumours, in an attempt to understand the molecular events 
that take place during each stage of tumour progression or the differences that may exist 
between subtypes of breast cancers. In the past, progress in achieving this has been 
hindered by the practical aspects of acquiring high quality RNA in sufficient quantities 
from pure subpopulations of cells to apply onto expensive, high-throughput, genome-
wide platforms. Commonly, RNA is extracted from crude normal or tumour specimens, 
which are bound to contain a heterogenous mix of cells, simply due to the nature of 
tissues. Heterogenous tissue may confound molecular analysis because it is currently 
impossible to discern which cells contribute to which cellular constituents to a given 
tissue lysate. Take for example, a tissue comprising of 80% tumour, 10% stroma and 
10% infiltrating lymphocytes. Although only a minority, it remains unknown how much 
the 10% lymphocyte population may contribute to the fold changes in expression of 
certain genes. Furthermore, to compare this tumour to another tumour that may have, say, 
75% tumour, 20% stroma and 5% infiltrating lymphocytes, may further compound the 
inaccuracy of results obtained. Tumour-stroma interactions and the tumour 
microenvironment are now regarded as important factors in tumour development and 





Historically, morphological analysis by direct microscopic visualisation of cells and 
tissue was the basis for defining disease diagnosis, for example, diagnosis of breast ductal 
carcinoma in situ versus invasive ductal carcinoma. In addition, clinical experience has 
shown that certain tumours will have different prognosis based on histology, for example, 
shape of cell, mitotic index, degree of differentiation, etc. More often than not, a single 
tumour will have a mixture of tumour subtypes, the most obvious example being IDCs 
that is often admixed with DCIS. To be able to study the molecular differences that may 
exist between these cell subpopulations from a single tumour source would also greatly 
minimise the effects of another major compounding factor, interpatient variability.  
 
In our study, we were able to successfully combine laser capture microdissection, RNA 
amplification and microarray technologies to generate epithelial specific gene expression 
profiles of premalignant, preinvasive and invasive stages of breast cancer from discrete 
subpopulations of cells within histologically complex tumour specimens. Specifically, we 
have shown that careful preparation and staining of tissue sections, microdissection of a 
reasonable amount of cells, qualitative and quantitative assessment of isolated RNA, and 
inclusion of internal controls can greatly contribute to the success of this approach. 
Hence, despite the small number of patient samples (n=3), we feel that important 
observations can be made from this study, strictly because of the quality of input material 
in the study. To a certain degree, we have proven the reliability of our microarray 





Nevertheless, we acknowledge that the functional significance of findings from our 
microarray data will require additional studies using a larger cohort of specimens and 
more sophisticated bioinformatic approaches. Of more immediate importance however, is 
the demonstration of how LCM can be easily coupled to microarray technology to allow 
study of the molecular pathology and evolution of tumour cells in complex breast tumour 
specimens. Although it is very difficult to verify EMT experimentally in vivo due to the 
transient and reversible nature of the process, and the fact that only a minority proportion 
of cells undergo EMT, expression analysis did help identify a molecular signature linked 
to this phenomenon. The ultimate goal of molecular profiling is to eventually provide a 















5.2 Chronology of EMT Events in Breast Cancer Progression 
Our study revealed molecular changes that occur at the normal to DCIS transition, and 
further changes that occur at the DCIS to IDC transition. The chronology of these events 
may provide crucial clues as to which genes contribute to the switching of phenotypes 
and acquisition of invasive attributes in neoplastic cells. We were particularly interested 
in the expression changes of EMT-related genes.   
 
We observed that deregulation of EMT-related genes involved in the control of cell 
proliferation and differentiation, regulation of transcription, metabolism and transport as 
well as signal transduction are more frequently altered at the in situ stage. Meanwhile, 
EMT-related genes involved in cell adhesion and motility, extracellular matrix 
remodeling and proteolysis were deregulated more at the invasive stage (Figure 15). 
Interesting and noteworthy genes identified through our study are summarised in Figure 
32.  
 
5.3 Networks of Molecules Involved 
A number of genes identified in our study seem to belong to common networks and 
pathways and have varying degrees of interaction and is schematically represented in 





















Figure 32. Schematic model portraying some of the more noteworthy genes that are differentially expressed during breast 
cancer progression. EMT is a multi-step process, whereby expression of EMT-related genes is altered as cells transform from 
normal to malignant, pre-invasive DCIS, and accumulate further as they progress from DCIS to IDC. Genes labeled in red were 
validated by IHC. Images of cells were modified from Thiery et al. (2002) Nat Rev Cancer.   
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Figure 33. Schematic representation of molecular networks and pathways involved in EMT, based on the results of our study. 
EMT-related genes centre on those involved in cell adhesion, signal transduction and regulation of transcription, although not all of 
the genes identified to be differentially expressed in our study are represented here. Wnt, MAPK and TGF-β signaling pathways are 
likely to be involved. Boxes labeled green show molecules that are upregulated whereas red indicate those that are downregulated. 
Solid lines denote direct interaction; dashed lines denote indirect interactions involving multiple downstream molecules that are not 
shown. This schematic diagram is drawn based upon known pathways available on the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) website, which is freely accessible online.   
 
General Discussion 
5.4 Future Work 
In our study, the tumour specimens we studied consistent of invasive ductal carcinomas 
of the breast. There is however, a less common subtype of breast cancer known as 
metaplastic carcinoma, also known as spindle carcinoma, carcinosarcoma or sarcomatoid 
carcinoma. Metaplastic carcinomas have a peculiar histomorphology that constitutes a 
mixture of carcinoma (tumours of epithelial origin) and sarcoma (tumours of 
mesenchymal origin). Classically, it is believed that the two cancer types that coexist 
within a single tumour arose from different stem cells of epithelial and mesenchymal 
origin. However, recent progress in EMT studies raises the possibility that the two cancer 
types may in fact arise from epithelial cells that undergo EMT to exhibit mesenchymal 
attributes. The morphology of the sarcomatous component is characterised by a less 
cohesive and more fibroblastoid feature, which is very reminiscent of EMT, thus making 
metaplastic carcinoma a very intriguing in vivo model to study in future studies.  
 
Indeed, studying metaplastic carcinoma as a model of EMT was proposed by Thiery et al. 
a number of years ago in his landmark review on EMT in cancer progression25. To date, a 
number of publications have emerged with fascinating findings of metaplastic carcinoma 
being strongly associated with EMT and basal-like phenotype in breast cancer47,51, 







The results of our study lead us to propose that EMT is a multi-step process, as opposed 
to a strict on-or-off, all-or-nothing event. Instead, changes in gene and protein expression 
related to EMT can and do occur as early as the normal to DCIS transition, but further 
accumulate as the cancer progresses from DCIS to IDC. These events eventually 
culminate in phenotypic changes sufficient for cellular invasion and metastasis. 
Beginning with subtle losses of epithelial markers such as claudins and cytokeratins in 
DCIS, followed by gain of mesenchymal markers such as N-cadherin, cadherin-11 and 
SPARC, tumour cells continually undergo EMT changes. Perhaps more extreme changes 
such as the complete loss of E-cadherin by Twist and Snail repression occurs even later 
as small multicellular aggregates or even solitary cells break away from the main lesion 
to invade distant stroma or extravasate into lymphovascular systems. Certainly, if a truly 
mesenchymal phenotype was achieved, it would become extremely difficult to 
microscopically identify or distinguish these tumour cells from resident normal stromal 
cells, which indeed is a limitation to EMT research at present. The danger with this is 
that, while conventional chemotherapy may target the bulk of the tumour, these now 
phenotypically and behaviourally different tumour cells may escape treatment and pose a 
risk for an even more aggressive tumour should relapse occur. Already, much work has 
been done to show that EMT is associated with poorer prognosis and decreased survival. 
Therefore, it is imperative that the chronology of EMT events and their trigger 
mechanism are elucidated because identification of new EMT inhibitors could hold the 
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8.1 APPENDIX A: GENERAL CHEMICALS 
 
First Base 
Phosphate Buffered Saline, pH 7.4 
0.5 M EDTA, pH 8.0 
 












Sinopharm Chemical Reagent Co. 









8.2 APPENDIX B: BUFFERS AND SOLUTIONS 
 
Tris-EDTA Buffer, pH 9.0 (10X concentration) 
6.05 g Tris-Base 
10 ml EDTA, 0.5 M, pH 8.0 
2.5 ml Tween-20 
 
PBS, 0.1% BSA, 0.01% Sodium Azide 
0.05 g sodium azide 
0.5 g bovine serum albumin 
50 ml PBS 
 
3% H2O2-PBS 
1 ml 30% H2O2 
9 ml PBS 
 
 
